<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2300,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/3755babe47b344ed8418839cff2740e9'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/3755babe47b344ed8418839cff2740e9'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1IUCOI003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1IUCOI003">Previous Result: <span>Brown v. Town &amp; Country Masonry &amp; Tuckpo...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1IUCF8003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1IUCF8003">Next Result: <span>Boston v. SKO Brenner American, Inc., No...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), Court Opinion'>
United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), Court Opinion</div>
<div class='docId'>X1IUBCK003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>United States v. Caronia</div>
<div class='displayCitation'>2012 BL 316528</div>
<div class='displayCitation'>703 F.3d 149</div>
<div class='displayCitation'>bna a0d5p2k5z1</div>
<div class='displayCitation'>wkf2case:26711754</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1IUBCK003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="United States v. Caronia" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1IUBCK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1IUBCK003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1IUBCK003" /><input id="title" name="title" type="hidden" value="United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="3755babe47b344ed8418839cff2740e9" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1IUBCK003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%33%37%35%35babe%34%37b%33%34%34ed%38%34%31%38%38%33%39cff%32%37%34%30e%39%2Fdocument%2FX%31IUBCK%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/bcite/X1IUBCK003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/bcite/X1IUBCK003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/bcite/X1IUBCK003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/related_content/X1IUBCK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1750581510147";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">703 F.3d 149</div>
<div class="cite" data-cite-type="DocketNumber">Docket No. 09-5006-cr.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 316528</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Second Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
UNITED STATES Of America, Appellee, v. Alfred CARONIA,
Defendant-Appellant.<a HREF="#fn*00" name="fnref_fn*00">[fn*]</a>
</center></p>
<hr align="center" width="65%">
<p><center>
Docket No. 09-5006-cr.
</center></p>
<p><center>
Argued: December 2, 2010.
</center></p>
<p><center>
Decided: December 3, 2012.
</center></p>
<p><center>
<span class="fr"><a HREF="#fnref_fn*00" name="fn*00">[fn*]</a></span> The Clerk of the Court is directed to amend the official caption in
accordance with the above.
</center></p>
<div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Eastern District of New
York, Eric Nicholas Vitaliano, J.

[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>

[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>

<span CLASS="page_no" data-cite="703 f 3d 152" data-cite-type="PrimaryFederalReporter" data-cite-pageno="152" data-primary-citation="703 F.3d 149">[*152]</span> Douglas Letter and Martin Coffey (Jo Ann M. Navickas, Assistant United
States Attorney, Scott R. McIntosh, Attorney, Appellate Division, United
States Department of Justice, Anne K. Walsh, Associate Chief Counsel, Office
of General Counsel, Food and Drug Division, on the brief), for Loretta E.
Lynch, United States Attorney for the Eastern District of New York,
Brooklyn, NY, for Appellee.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Jennifer L. McCann (Thomas F. Liotti, on the brief), Law Offices of Thomas
F. Liotti, Garden City, NY, for Defendant-Appellant.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Eric E. Murphy, Jones Day (Michael A. Carvin, Jones Day, Daniel J. Popeo,
Richard A. Samp, Washington Legal Foundation, on the brief), for Amicus
Curiae Washington Legal Foundation.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Joan McPhee, Ropes &amp; Gray LLP (Douglas Hallward-Driemeier, Alan Bennett,
Ropes &amp; Gray LLP, and Paul Kalb, Coleen Klasmeier, Sidley Austin LLP, on the
brief), for Amicus Curiae The Medical Information Working Group.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before: RAGGI, LIVINGSTON, and CHIN, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
CHIN, Circuit Judge:
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Judge LIVINGSTON dissents in a separate opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Defendant-appellant Alfred Caronia appeals from a judgment of conviction
entered in the United States District Court for the Eastern District of New
York (Eric N. Vitaliano, <i>J.</i>) on November 30, 2009, following a jury trial at
which Caronia was found guilty of conspiracy to introduce a misbranded drug
into interstate commerce, a misdemeanor violation of <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a) and
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)(1)&amp;summary=yes#jcite">333</a>(a)(1). Specifically, Caronia, a pharmaceutical sales representative,
promoted the drug Xyrem for "off-label use," that is, for a purpose not
approved by the U.S. Food and Drug Administration (the "FDA"). Caronia
argues that he was convicted for his speech &mdash; for promoting an FDA-approved
drug for off-label use &mdash; in violation of his right of free speech under the
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=U.S.%20Const.%20Amend%20I&amp;summary=yes#jcite">First Amendment</a>. We agree. Accordingly, we vacate the judgment of conviction
and remand the case to the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>STATEMENT OF THE CASE</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>1. The Regulatory Scheme</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under the Federal Food, Drug and Cosmetic Act (the "FDCA"), before drugs
are
<span CLASS="page_no" data-cite="703 f 3d 153" data-cite-type="PrimaryFederalReporter" data-cite-pageno="153" data-primary-citation="703 F.3d 149">[*153]</span> 
distributed into interstate commerce, they must be approved by the FDA for
specific uses. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(a). To obtain FDA approval, drug
manufacturers are required to demonstrate, through clinical trials, the
safety and efficacy of a new drug for each intended use or indication.
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(d); <i>see Weinberger v. Hynson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8HF?jcsearch=412%20us%20609&amp;summary=yes#jcite">412 U.S. 609</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8HF?jcsearch=412%20us%20609&amp;summary=yes#jcite">612-14</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8HF?jcsearch=93%20supreme%20court%202469&amp;summary=yes#jcite">93 S.Ct. 2469</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8HF?jcsearch=37%20l%20ed%202d%20207&amp;summary=yes#jcite">37 L.Ed.2d 207</a> (1973).<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Once FDA-approved, prescription drugs can be prescribed by doctors for
both FDA-approved and-unapproved uses; the FDA generally does not regulate
how physicians use approved drugs. <i>See Buckman Co. v. Plaintiffs' Legal</i>
<i>Comm.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. 341</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">350</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4U3HP?jcsearch=148%20l%20ed%202d%20854&amp;summary=yes#jcite">148 L.Ed.2d 854</a> (2001); <i>Weaver v.</i>
<i>Reagen</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5402C?jcsearch=886%20f%202d%20194&amp;summary=yes#jcite">886 F.2d 194</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5402C?jcsearch=886%20f%202d%20194&amp;summary=yes#jcite">198</a> (8th Cir.1989); John E. Osborn, <i>Can I Tell You The</i>
<i>Truth? A Comparative Perspective on Regulating Off-Label Scientific and</i>
<i>Medical Information</i>, 10 Yale J. Health Pol'y L. &amp; Ethics 299, 303 (2010)
("Physicians may prescribe FDA-approved drugs . . . for any therapeutic use
that is appropriate in their medical judgment."); Randall S. Stafford,
<i>Regulating Off-Label Drug Use: Rethinking the Role of the FDA</i>, 358 N. Engl.
J. Med. 1427, 1427 (2008) (discussing 2003 study of 160 common drugs where
off-label use accounted for approximately 21 percent of prescriptions).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Indeed, courts and the FDA have recognized the propriety and potential
public value of unapproved or off-label drug use. <i>See Buckman</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 350</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a> (Off-label use is an "accepted and necessary
corollary of the FDA's mission to regulate in this area without directly
interfering with the practice of medicine."); <i>Weaver</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5402C?jcsearch=886%20f%202d%20194&amp;summary=yes#jcite">886 F.2d at 198-99</a>
("FDA[-]approved indications were not intended to limit or interfere with
the practice of medicine nor to preclude physicians from using their best
judgment in the interest of the patient." (internal quotation marks
omitted)); U.S. Food and Drug Administration, <i>Draft Guidance, Good Reprint</i>
<i>Practices for the Distribution of Medical Journal Articles and Medical or</i>
<i>Scientific Reference Publications on Unapproved New Uses of Approved Drugs</i>
<i>and Approved or Cleared Medical Devices</i> 3 (2009) ("[o]ff-label uses or
treatment regimens <span CLASS="page_no" data-cite="2012 bl 316528 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> may be important and may even constitute a
medically[-]recognized standard of care.").<a HREF="#fn200" name="fnref_fn200">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA itself has observed:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Once a drug has been approved for marketing, a physician may
    prescribe it for uses or in treatment regimens or patient
    populations that are not included in approved labeling. Such
    "unapproved" or, more precisely, "unlabeled" uses may be appropriate
    and rational in certain circumstances, and may, in fact, reflect
    approaches to drug therapy that have been extensively reported in
    medical literature.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
U.S. Food and Drug Administration, <i>FDA Drug Bulletin</i>, 12 FDA Drug Bull. 1, 5
(1982).
<span CLASS="page_no" data-cite="703 f 3d 154" data-cite-type="PrimaryFederalReporter" data-cite-pageno="154" data-primary-citation="703 F.3d 149">[*154]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDCA prohibits "misbranding," or "[t]he introduction or delivery for
introduction into interstate commerce of any . . . drug . . . that is . . .
misbranded." <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a). A drug is misbranded if, <i>inter alia</i>, its
labeling fails to bear "adequate directions for use," <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(f)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(f),
which FDA regulations define as "directions under which the lay[person] can
use a drug safely and for the purposes for which it is intended," <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20C.F.R.%20%C2%A7%20201.5&amp;summary=yes#jcite">21 C.F.R.
&sect; 201.5</a>.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> FDA regulations define intended use by reference to "the
objective intent of the persons legally responsible for the labeling of
drugs," which may be demonstrated by, among other evidence, "oral or written
statements by such persons or their representatives" and "the circumstances
that the article is, with the knowledge of such persons or their
representatives, offered and used for a purpose for which it is neither
labeled nor advertised." <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ49S003?jcsearch=21%20C.F.R.%20%20201.128&amp;summary=yes#jcite">21 C.F.R. &sect; 201.128</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The consequences for misbranding are criminal. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)(2)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(a)(2)
("[I]f any person commits such a violation . . . such persons shall be
imprisoned for not more than three years or fined not more than $10,000, or
both."). Pharmaceutical manufacturers and their representatives can face
misdemeanor charges for misbranding or felony charges for fraudulent
misbranding. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(a); <i>see</i> Osborn, <i>Can I Tell You The Truth?,</i>
<i>supra</i>, at 328-29 (collecting cases). The government has repeatedly
prosecuted &mdash; and obtained convictions against &mdash; pharmaceutical companies and
their representatives for misbranding based on their off-label promotion.
<i>See, e.g.</i>, Judgment, <i>United States v. Glaxo Smith Kline, LLC</i>, <cite>12-cr-10206</cite>
(RWZ), ECF Doc. No. 13 (D.Mass. July 10, 2012) (Information, <i>Glaxo</i>
<i>SmithK-line</i>, No. <cite>12-cr-10206</cite> (RWZ), ECF Doc. No. 1 (D.Mass. July 2, 2012));
Judgment, <i>United States v. Merck Sharp &amp; Dohme Corp.</i>, No. <cite>11-cr-10384</cite> (PBS),
ECF Doc. No. 30 (D.Mass. May 18, 2012) (Information, <i>Merck</i>, No. <cite>11-cr-10384</cite>
(PBS), ECF Doc. No. 1 (D.Mass. Nov. 22, 2011)); Agreed Order of Forfeiture,
<i>United States v. Abbott Labs.</i>, No. <cite>12-cr-26</cite> (SGW), ECF Doc. No. 7 (W.D.Va.
May 7, 2012) (as a result of the guilty plea to the Information
(Information, <i>Abbott</i>, No. <cite>12-cr-26</cite> (SGW), ECF Doc. No. 5-1 (W.D.Va. May 7,
2012))); Judgment, <i>United States v. Allergan, Inc.</i>, No. <cite>10-cr-375</cite> (ODE), ECF
Doc. No. 20 (N.D.Ga. Oct. 7, 2010) (Information, <i>Allergan</i>, No. <cite>10-cr-375</cite>
(ODE), ECF Doc. No. 1 (N.D.Ga. Sept. 1, 2010)); <i>see</i> Sentencing Transcript,
<i>Merck</i>, No. <cite>11-cr-10384</cite> (PBS), ECF Doc. No. 27 (D. Mass. April 30, 2012) ("I
want to emphasize that off-label marketing has been . . . a big problem. . .
. I hope in a way that the . . . fact that all these cases are being pressed
by the federal and state governments, the 44 state Attorney Generals, will
be a signal that it isn't acceptable conduct."); <i>see also</i> Press Release,
<span CLASS="page_no" data-cite="2012 bl 316528 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> U.S. Department of Justice, <i>GlaxoSmithKline to Plead Guilty and Pay $3</i>
<i>Billion to Resolve Fraud Allegations and Failure to Report Safety Data,</i>
<i>Largest Health Care Fraud Settlement in U.S. History</i> (July 2, 2012); Osborn,
<i>Can I Tell You The Truth?, <cite>supra</cite></i>, at 328-29.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDCA and its accompanying regulations do not expressly prohibit the
"promotion" or "marketing" of drugs for off-label use. The regulations do
recognize that promotional statements by a pharmaceutical company or its
representatives can serve as proof of a <span CLASS="page_no" data-cite="703 f 3d 155" data-cite-type="PrimaryFederalReporter" data-cite-pageno="155" data-primary-citation="703 F.3d 149">[*155]</span> drug's intended use.

<i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20cfr%20201%205&amp;summary=yes#jcite">21 C.F.R. &sect; 201.5</a>. Off-label promotional statements could thus presumably
constitute evidence of an intended use of a drug that the FDA has not
approved. <i>See <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20C.F.R.%20%20201.5&amp;summary=yes#jcite">id</a>.</i> The FDA, however, has concluded that "[a]n approved drug
that is marketed for an unapproved use (whether in labeling or not) is
misbranded because the labeling of such drug does not include`adequate
directions for use.'" <i>See</i> FDA, Draft Guidance, <i><cite>supra</cite></i>, at 2-3 (quoting
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(f)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(f)); <i>accord United States v. Caronia</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20f%20supp%202d%20385&amp;summary=yes#jcite">576 F.Supp.2d 385</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20f%20supp%202d%20385&amp;summary=yes#jcite">392</a>
n. 5 (E.D.N.Y.2008); <i>see also</i> Gov't Br. 48 n.18 (contending no set of
directions can constitute adequate labeling for drug's off-label use). Thus,
the government has treated promotional speech as more than merely evidence
of a drug's intended use &mdash; it has construed the FDCA to prohibit promotional
speech as misbranding itself.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>2. The Facts</i></b><a HREF="#fn400" name="fnref_fn400">[fn4]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>a. Orphan Medical and Xyrem</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Orphan Medical, Inc. ("Orphan"), now known as Jazz Pharmaceutical, was a
Delaware-incorporated pharmaceutical company that primarily developed drugs
to treat pain, sleep disorders, and central nervous system disorders. Orphan
manufactured the drug Xyrem, a powerful central nervous system depressant.
In 2005, after Jazz Pharmaceuticals acquired Orphan, Jazz continued to
manufacture and sell Xyrem, grossing $20 million in combined Xyrem sales in
2005.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Xyrem can cause serious side effects, including difficulty breathing while
asleep, confusion, abnormal thinking, depression, nausea, vomiting,
dizziness, headache, bedwetting, and sleepwalking. If abused, Xyrem can
cause additional medical problems, including seizures, dependence, severe
withdrawal, coma, and death.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Xyrem's active ingredient is gamma-hydroxybutryate ("GHB"). GHB has been
federally classified as the "date rape drug" for its use in the commission
of sexual assaults.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>b. The FDA's Regulation of Xyrem</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite the risks associated with Xyrem and GHB, the FDA approved Xyrem
for two medical indications. In July 2002, the FDA approved Xyrem to treat
narcolepsy patients who experience cataplexy, a condition associated with
weak or paralyzed muscles. In November 2005, the FDA approved Xyrem to treat
narcolepsy patients with excessive daytime sleepiness ("EDS"), a
neurological disorder caused by the brain's inability to regulate sleep-wake
cycles.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To protect against its serious safety concerns, in 2002, the FDA required
a "black box" warning to accompany Xyrem. The black box warning is the most
serious warning placed on prescription medication labels. Xyrem's black box
labeling stated, among other things, that the drug's safety and efficacy
were not established <span CLASS="page_no" data-cite="2012 bl 316528 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> in patients under 16 years of age, and the drug had
"very limited" experience among elderly patients.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To identify patients suffering side effects from the drug, the FDA also
regulated Xyrem distribution, allowing only one centralized Missouri
pharmacy to distribute Xyrem nationally.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>c. Caronia's Employment with Orphan</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In March 2005, Orphan hired Caronia as a Specialty Sales Consultant to
promote
<span CLASS="page_no" data-cite="703 f 3d 156" data-cite-type="PrimaryFederalReporter" data-cite-pageno="156" data-primary-citation="703 F.3d 149">[*156]</span> 
Xyrem. Caronia primarily worked in Queens, Nassau, and Suffolk counties.
Caronia's salary was based on his individual sales.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In July 2005, Caronia started Orphan's "speaker programs" for Xyrem.
Speaker programs enlist physicians, for pay, to speak to other physicians
about FDA-approved drug use. Orphan's speaker programs for Xyrem presented
the benefits of the drug among patients with cataplexy and narcolepsy.
Orphan hired Dr. Peter Gleason to promote Xyrem through its speaker
programs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under Orphan's procedures, if Caronia, as a sales consultant for Xyrem,
was asked about the off-label use of Xyrem, he was not permitted to answer;
instead, when such questions were posed, Orphan sales consultants would fill
out "medical information request forms" and send them to Orphan, and Orphan
would send information to the inquiring physician.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> In contrast,
physicians employed by Orphan as promotional speakers for Xyrem were
permitted to answer off-label use questions; their responses were often
informed by their own experiences with Xyrem.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>d. Caronia's Participation in the Conspiracy</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the spring of 2005, the federal government launched an investigation of
Orphan and Gleason. The investigation focused on the off-label promotion of
Xyrem. Caronia and Gleason were audio-recorded on two occasions as they
promoted Xyrem for unapproved uses, including unapproved indications and
unapproved subpopulations. The first conversation was recorded on October
26, 2005 between Caronia and Dr. Stephen Charno, a physician who, as a
government cooperator, posed as a prospective Xyrem customer. The second
conversation was recorded on November 2, 2005; it taped a meeting arranged
by Caronia to introduce Charno to Gleason.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 26, 2005, Caronia plainly promoted the use of Xyrem in
unapproved indications with Charno:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Caronia]: And right now the indication is for narcolepsy with
    cataplexy . . . excessive daytime . . . and fragmented sleep, but
    because of the properties that . . . it has it's going to insomnia,
    Fibromyalgia[,] periodic leg movement, restless leg, ahh also
    looking at ahh Parkinson's and . . . other sleep disorders are
    underway such as MS.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Charno]: Okay, so then so then it could be used for muscle
    disorders and chronic pain and . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Caronia]: Right.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Charno]: . . . and daytime fatigue and excessive sleepiness and
    stuff like that?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Caronia]: Absolutely. Absolutely. Ahh with the Fibromyalgia.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(October 26, 2005 Recording Tr. (I) at 4-5). Caronia further directed Charno
to list different "diagnosis codes" when prescribing Xyrem, for insurance
purposes, including Fibromyalgia, chronic fatigue, or chronic pain.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On separate occasions, Caronia and Gleason each explained to prospective
<span CLASS="page_no" data-cite="2012 bl 316528 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> physician-customers that Xyrem could be used with patients under age
sixteen, an unapproved Xyrem subpopulation:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Caronia]: Um, the youngest patients we have are sixteen in the
    studies as old as sixty-five. Ahh there have been reports
<span CLASS="page_no" data-cite="703 f 3d 157" data-cite-type="PrimaryFederalReporter" data-cite-pageno="157" data-primary-citation="703 F.3d 149">[*157]</span> 
    of patients as young as fourteen using it and obviously greater than
    sixty-five. It's a very safe drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(October 26, 2005 Recording Tr. (I) at 7).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [Gleason]: Well, it's actually approved for sixteen and above um,
    I've had people under thirteen and I've certainly talked to
    neurologists that have narcoleptics . . . between eight and ten . .
    . [but] I start at two-thirds the dose, but [if] they're real frail
    I only start with one-third the dose.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(November 2, 2005 Recording Tr. (II) at 51).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>3. Proceedings Below</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>a. The Charges</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On July 25, 2007, a grand jury returned its first Indictment against
Caronia. The charging document at issue on this appeal, however, is the
Superseding Information filed by the government on August 19, 2008, which
charged Caronia with the following two misdemeanor offenses:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Count One: Conspiracy to introduce a misbranded drug into
    interstate commerce in violation of <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a) and
    <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)(2)&amp;summary=yes#jcite">333</a>(a)(2); and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Count Two: Introducing a misbranded drug, Xyrem, into interstate
    commerce, in violation of <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a) and <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)(2)&amp;summary=yes#jcite">333</a>(a)(2).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(Inf. &para;&para; 12-17).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With respect to Count One, the Information alleged a two-prong conspiracy.
The first prong charged that between approximately March 2005 and March
2006, Caronia, "together with others, did knowingly and intentionally
conspire to" introduce Xyrem and cause the introduction of Xyrem into
interstate commerce when Xyrem was misbranded within the meaning of the
FDCA. (Inf. &para; 13). The second prong alleged that "[i]t was part of the
conspiracy that [Caronia], together with others, marketed Xyrem for medical
indications that were not approved by [the] FDA when, as [they] . . . well
knew and believed, Xyrem's labeling lacked adequate directions for and
warnings against such uses, where such uses could be dangerous to the user's
health." (Inf. &para; 14).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Information alleged, in Count One, that Caronia, "together with
others, committed and caused to be committed," the following two overt acts.
(Inf. &para; 15).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      a. On or about October 26th, 2005, . . . Caronia promoted Xyrem to
    [Charno], a physician, so as to cause [Charno] to prescribe Xyrem
    for fibromyalgia, excessive daytime sleepiness, muscle disorders,
    chronic pain and fatigue, which were "off-label" indications.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      b. On or about November 2, 2005, . . . Caronia introduced [Charno]
    to [Gleason], a physician, who was paid by Orphan and whom Orphan
    used to promote Xyrem for "off-label" indications, including
    fibromyalgia, excessive daytime sleepiness, weight loss and chronic
    fatigue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(Inf. &para;&para; 15(a), (b)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  With respect to Count Two, the Information alleged that between
approximately March 2005 and March 2006, Caronia "was marketing Xyrem for
medical indications that were not approved by [the] FDA when, as the
defendant then and there well knew and believed, Xyrem's labeling lacked
adequate directions for such uses and adequate warnings against such uses
where uses could be dangerous to the user's health." (Inf. &para; 17).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, the Information alleged: "A drug that was marketed <span CLASS="page_no" data-cite="2012 bl 316528 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> to the
public for an`off-label' indication or use did not contain`adequate
directions for use' because such an`off-label' indication or use and related
information were not included
<span CLASS="page_no" data-cite="703 f 3d 158" data-cite-type="PrimaryFederalReporter" data-cite-pageno="158" data-primary-citation="703 F.3d 149">[*158]</span> 
in the FDA-approved labeling for the drug." (Inf. &para; 8). The Information
further stated: "Xyrem's labeling lacked adequate directions for such uses
and adequate warnings against such uses where such uses could be dangerous
to the user's health." (Inf. &para;&para; 14, 17).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Orphan and Gleason were also charged under the misbranding provisions of
the FDCA; both pled guilty. <i>United States v. Caronia</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20f%20supp%202d%20385&amp;summary=yes#jcite">576 F.Supp.2d at 389-90</a> &amp; n. 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>b. Caronia's Pre-Trial Motion to Dismiss</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 9, 2007, before trial, Caronia moved to dismiss the charges
against him. In part, Caronia argued that the application of the FDCA's
misbranding provisions to his off-label promotional statements
unconstitutionally restricted his right to free speech under the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=U.S.%20Const.%20Amend%20I&amp;summary=yes#jcite">First
Amendment</a> and that the provisions were unconstitutionally vague and broad.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On September 11, 2008, the district court denied Caronia's motion,
including his First Amendment challenge, which it recognized as raising
constitutional issues "very much unsettled, not only in this circuit but
nationwide." <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20F.%20Supp.%202d%20385&amp;summary=yes#jcite">Id. at 403</a>. Although ruling for the government, the district
court rejected the government's argument that Caronia was being prosecuted
for the unlawful conduct of misbranding and conspiring to misbrand a drug
and not for his promotional speech, the latter of which the government
contended only constituted proof of Xyrem's intended use. <i>See </i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20F.%20Supp.%202d%20385&amp;summary=yes#jcite">id. at 394-95</a>.
The court observed that "the criminal information . . . allege[d] Caronia's
promotion of off-label uses of an FDA-approved drug," and concluded that
Caronia stood charged with a crime the <i>actus reus</i> of which was First
Amendment speech. <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20F.%20Supp.%202d%20385&amp;summary=yes#jcite">Id. at 395</a>.Nevertheless, the district court held that, to
the extent the FDCA criminalizes speech, the law passed constitutional
muster under the commercial speech doctrine because the FDCA was not more
extensive than necessary to achieve the FDA's objectives. <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1C8RUG003?jcsearch=576%20F.%20Supp.%202d%20385&amp;summary=yes#jcite">Id. at 401-02</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>c. The Trial</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The case was tried before a jury from October 6 to October 16, 2008.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The record makes clear that the government prosecuted Caronia for his
off-label promotion, in violation of the FDCA. The government, in its
summation and rebuttal, repeatedly asserted that Caronia was guilty because
he, with others, conspired to promote and market Xyrem for off-label use.
For example, the government argued:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      &bull; "[Caronia is] promoting, he's marketing a dangerous drug for use
    not approved by the FDA" (<i></i><cite>id. at 825</cite>);
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      &bull; "He knew the rules: you can't promote and market Xyrem for uses
    that have not been approved by the FDA. He admits it" (<i></i><cite>id. at 839</cite>);
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      &bull; "[Caronia] conspired through some act of misbranding, and that
    act of misbranding . . . was the promotion on October 26th and
    November 2nd[,] marketing [a] drug for unapproved uses" (<i></i><cite>id. at
    848</cite>);
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      &bull; "That's misbranding. That's promoting and marketing a drug by a
    pharmaceutical company representative for muscle disorders, chronic
    pain, daytime fatigue, excessive sleepiness" (<i></i><cite>id. at 870</cite>); and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      &bull; "[Caronia was] promoting, promoting, selling, <span CLASS="page_no" data-cite="2012 bl 316528 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> selling, trying to
    get Charno to prescribe Xyrem. He tried on the 26th. He tried with
    Gleason on the 2nd" (<i></i><cite>id. at 875</cite>).<span CLASS="page_no" data-cite="703 f 3d 159" data-cite-type="PrimaryFederalReporter" data-cite-pageno="159" data-primary-citation="703 F.3d 149">[*159]</span> <a HREF="#fn600" name="fnref_fn600">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Thus, the government's theory of prosecution identified Caronia's speech
alone as the proscribed conduct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court, in its jury charge, reinforced the idea that Caronia's
promotional speech was enough to support a guilty verdict:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A misbranded drug may be shown by a promotion of the drug by a
    distributor for an intended use different from the use for which the
    drug was approved by the [FDA].
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The manufacturer, its agents, representatives and employees, are
    not permitted to promote uses for a drug that have not been cleared
    by the United States Food and Drug Administration. These non-cleared
    uses are commonly referred to as`off-label uses' because they are
    not included in the drug's labeling.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(Trial Tr. 920-21).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prior to jury deliberation, the district court provided a proposed verdict
sheet to the parties. With respect to Count One, the verdict sheet read as
follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. How do you find defendant, ALFRED CARONIA, on Count One of the
    Information?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) Conspiracy to introduce or deliver for introduction into
    interstate commerce a drug, Xyrem, that was misbranded?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      NOT GUILTY___ GUILTY___
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (b) Conspiracy to do an act with respect to a drug, Xyrem, when
    such drug was held for sale after shipment in interstate commerce
    when such act would result in Xyrem being misbranded?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      NOT GUILTY ___ GUILTY ___
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
(Verdict Sheet, ECF Doc. No. 103, <i>United States v. Caronia</i>, <cite>No. 06 Cr. 229</cite>
(E.D.N.Y. Oct. 23, 2008)). The district court overruled Caronia's objection
that the verdict sheet was erroneous and therefore permitted the jury to
reach an inconsistent verdict.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 23, 2008, the jury found Caronia guilty as to the first prong
of Count One of the Information (Question 1(a)): conspiracy to introduce a
misbranded drug into interstate commerce under <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEHRNC003?jcsearch=18%20U.S.C.%20%20371(a)&amp;summary=yes#jcite">18 U.S.C. &sect; 371</a>(a) and
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a). As to the second marketing prong of Count One (Question
1(b)), the jury found Caronia not guilty. The jury also found Caronia not
guilty of Count Two of the Information.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>d. Caronia's Post-Trial Motion for Acquittal</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After the jury verdict and before judgment was entered, Caronia renewed
his Rule 29 motion for acquittal. <i>See</i> Fed.R.Crim.P. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1HREGQ003?jcsearch=Fed.%20R.%20Crim.%20P.%2029&amp;summary=yes#jcite">29</a>. On December 13,
2008, after
<span CLASS="page_no" data-cite="703 f 3d 160" data-cite-type="PrimaryFederalReporter" data-cite-pageno="160" data-primary-citation="703 F.3d 149">[*160]</span> 
briefing, the district court denied the motion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>e. Caronia's Sentence</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On November 30, 2009, the district court sentenced Caronia to one year of
probation, 100 hours of community service, and a $25 special assessment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This appeal followed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>DISCUSSION</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Caronia principally argues that the misbranding provisions of
the FDCA prohibit off-label promotion, and therefore, unconstitutionally
restrict speech.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> Caronia argues that the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> does not
permit the government to prohibit and criminalize a pharmaceutical
manufacturer's truthful and non-misleading promotion of an FDA-approved drug
to physicians for off-label use where such use is not itself illegal and
others are permitted to engage in such speech.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review Caronia's First Amendment challenge to his conspiracy conviction
<i>de novo. See Conn. Bar Ass'n v. United States</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1E54R4003?jcsearch=620%20f%203d%2081&amp;summary=yes#jcite">620 F.3d 81</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1E54R4003?jcsearch=620%20f%203d%2081&amp;summary=yes#jcite">89</a> (2d Cir.2010)
("We <span CLASS="page_no" data-cite="2012 bl 316528 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> review constitutional challenges to a federal statute <i>de novo."); see</i>
<i>also United States v. Dhafir</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X15J8BG003?jcsearch=461%20f%203d%20211&amp;summary=yes#jcite">461 F.3d 211</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X15J8BG003?jcsearch=461%20f%203d%20211&amp;summary=yes#jcite">215</a> (2d Cir.2006) (same). We
agree that Caronia's conviction must be vacated, but for narrower reasons
than he urges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the FDCA makes it a crime to misbrand or conspire to misbrand a
drug, the statute and its accompanying regulations do not expressly prohibit
or criminalize off-label promotion. <i>See supra</i> 153-55. Rather, the FDCA and
FDA regulations reference "promotion" only as evidence of a drug's intended
use. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ49S003?jcsearch=21%20cfr%20201%20128&amp;summary=yes#jcite">21 C.F.R. &sect; 201.128</a> (discussing how drug's intended use can be
demonstrated). Thus, under the principle of constitutional avoidance,
explained <i>infra</i>, we construe the FDCA as not criminalizing the simple
promotion of a drug's off-label use because such a construction would raise
First Amendment concerns. Because we conclude from the record in this case
that the government prosecuted Caronia for mere off-label promotion and the
district court instructed the jury that it could convict on that theory, we
vacate the judgment of conviction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We begin by addressing the government's contention that Caronia's
off-label promotion was used only as evidence of intent in this case.
Finding the government's argument unpersuasive, we turn to the principal
question on appeal: whether the government's prosecution of Caronia under
the FDCA only for promoting an FDA-approved drug for off-label use was
constitutionally permissible.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>I. Speech versus Evidence of Intent</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government contends &mdash; and the dissent agrees &mdash; that the First
Amendment is not implicated in this case. Specifically, the government
argues that "[p]romoting an approved drug for off-label uses is not itself a
prohibited act under the FDCA" and "the promotion of off-label uses plays an
<i>evidentiary</i> role in determining whether a drug is misbranded under
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(f)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(f)(1)." (Gov't Br. 51 (citing <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20usc%20331&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>)). The
government contends that Caronia was not prosecuted for his speech, but that
Caronia's promotion of Xyrem for off-label use served merely as "evidence of
intent," or evidence that the "off-label uses were intended ones[] for which
Xyrem's
<span CLASS="page_no" data-cite="703 f 3d 161" data-cite-type="PrimaryFederalReporter" data-cite-pageno="161" data-primary-citation="703 F.3d 149">[*161]</span> 
labeling failed to provide any directions." (Gov't Br. 52).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even assuming the government can offer evidence of a defendant's off-label
promotion to prove a drug's intended use and, thus, mislabeling for that
intended use,<a HREF="#fn800" name="fnref_fn800">[fn8]</a> that is not what happened in this case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, the government's contention that it did not prosecute Caronia for
promoting the off-label use of an FDA-approved drug is belied by its conduct
and arguments at trial. The excerpts quoted above demonstrate that the
government repeatedly argued that Caronia engaged in criminal conduct by
promoting and marketing the off-label use of Xyrem, an FDA-approved drug.
<i>See supra</i> 158-59 &amp; n. 7. The district court record thus confirms
overwhelmingly that Caronia was, in fact, prosecuted and convicted for
promoting Xyrem off-label. <i>See supra</i> 155-60. Indeed, in the government's
summation and rebuttal at trial, Caronia's off-label promotion of Xyrem is
highlighted over forty times. (<i>See</i> Trial Tr. 819-49, 870-80, 883-85).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, the government's assertion <span CLASS="page_no" data-cite="2012 bl 316528 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> now that it used Caronia's efforts to
promote Xyrem for off-label use only as evidence of intent is simply not
true. Even if the government could have used Caronia's speech as evidence of
intent, the district court record clearly shows that the government did not
so limit its use of that evidence. <i>See Mitchell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. at 489-90</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a> (instructing that, when speech is introduced as evidence of
intent, "`[s]uch testimony is to be scrutinized with care to be certain the
statements are not expressions of mere lawful and permissible difference of
opinion with our own government'" (quoting <i>Haupt v. United States</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C154?jcsearch=330%20us%20631&amp;summary=yes#jcite">330 U.S. 631</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C154?jcsearch=330%20us%20631&amp;summary=yes#jcite">642</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C154?jcsearch=67%20supreme%20court%20874&amp;summary=yes#jcite">67 S.Ct. 874</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=91%20l%20ed%201145&amp;summary=yes#jcite">91 L.Ed. 1145</a> (1947))). The government
never argued in summation or rebuttal that the promotion was evidence of
intent. (See Trial Tr. 819-49, 870-80, 883-85). The government never
suggested that Caronia engaged in any form of misbranding other than the
promotion of the off-label use of an FDA-approved drug. The government never
suggested, for example, that Caronia conspired to place false or deficient
labeling on a drug. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(a)-<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(n)&amp;summary=yes#jcite">(n)</a>. Rather, the record makes
clear that the government prosecuted Caronia <i>for</i> his promotion and marketing
efforts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Third, the government's summation and the district court's instruction
left the jury to understand that Caronia's speech was itself the proscribed
conduct. <i>See supra</i> 158-59. Indeed, the district court flatly stated to the
jury that pharmaceutical representatives are prohibited from engaging in
off-label promotion. <i>See id.</i> Although the district court explained the
remaining elements of misbranding and conspiring to misbrand to the jury,
this specific instruction &mdash; together with the government's summation &mdash; would
have led the jury to believe that Caronia's promotional speech was, by
itself, determinative of his guilt. <i>See generally United States v. Dyer</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X354LC?jcsearch=922%20f%202d%20105&amp;summary=yes#jcite">922 F.2d 105</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X354LC?jcsearch=922%20f%202d%20105&amp;summary=yes#jcite">107-08</a> (2d Cir.1990) (stating specific jury instruction may be
reviewed in isolation if "it is so far removed from the standards set by the
law that the appellate court is convinced that the jury might have been
misled" (internal quotation marks omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Fourth, the government clearly prosecuted Caronia for his words &mdash; -for his
speech. A pharmaceutical representative's promotion of an FDA-approved
drug's off-label use is speech. As the Supreme
<span CLASS="page_no" data-cite="703 f 3d 162" data-cite-type="PrimaryFederalReporter" data-cite-pageno="162" data-primary-citation="703 F.3d 149">[*162]</span> 
Court has held: "Speech in aid of pharmaceutical marketing . . . is a form
of expression protected by the Free Speech Clause of the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a>."
<i>Sorrell v. IMS Health, Inc.</i>, ___ U.S.___, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">2659</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a> (2011). Here, the proscribed conduct for which Caronia was
prosecuted was precisely his speech in aid of pharmaceutical marketing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, we conclude that the government did prosecute Caronia for his
speech, and we turn to whether the prosecution was permissible.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>II. The Prosecution of Caronia's Speech</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the government and the FDA have construed the FDCA's misbranding
provisions to prohibit off-label promotion by pharmaceutical manufacturers,
<i>see supra</i> 154-55; <i>see</i> FDA, <i>Draft Guidance, supra</i>, at 2-3, as we have
observed, the FDCA itself does not expressly prohibit or criminalize
off-label promotion. <i>See supra</i> 153-55. The FDCA defines misbranding in terms
of whether a drug's labeling <span CLASS="page_no" data-cite="2012 bl 316528 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> is adequate for its intended use, and permits
the government to prove intended use by reference to promotional statements
made by drug manufacturers or their representatives. <i>See id.</i> Assuming that
this approach to the use of evidence of speech is permissible,<a HREF="#fn900" name="fnref_fn900">[fn9]</a> it
affords little support to the government on this appeal because Caronia was
not prosecuted on this basis. Rather, the government's theory of prosecution
identified Caronia's speech alone as the proscribed conduct. The district
court accepted this theory.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To the extent there is any ambiguity as to whether off-label promotion is
tantamount to illegal misbranding, we construe the FDCA narrowly to avoid a
serious constitutional question. <i>See Shilling v. United States</i>,
<cite>___ U.S. ___</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DI86K003?jcsearch=130%20supreme%20court%202896&amp;summary=yes#jcite">130 S.Ct. 2896</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DI86K003?jcsearch=130%20supreme%20court%202896&amp;summary=yes#jcite">2929-30</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DI86K003?jcsearch=177%20l%20ed%202d%20619&amp;summary=yes#jcite">177 L.Ed.2d 619</a> (2010) (instructing
courts to "avoid constitutional difficulties by adopting a limiting
interpretation if such a construction is fairly possible" (internal
quotation marks and brackets omitted)); <i>Edward J. DeBartolo Corp. v. Fla.</i>
<i>Gulf Coast Bldg. &amp; Constr. Trades Council</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBIK?jcsearch=485%20us%20568&amp;summary=yes#jcite">485 U.S. 568</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBIK?jcsearch=485%20us%20568&amp;summary=yes#jcite">575</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=108%20supreme%20court%201392&amp;summary=yes#jcite">108 S.Ct. 1392</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBIK?jcsearch=99%20l%20ed%202d%20645&amp;summary=yes#jcite">99 L.Ed.2d 645</a> (1988); <i>Allstate Ins. Co. v. Serio</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2AHSB?jcsearch=261%20f%203d%20143&amp;summary=yes#jcite">261 F.3d 143</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2AHSB?jcsearch=261%20f%203d%20143&amp;summary=yes#jcite">150</a> (2d Cir.2001) ("Thus, the courts will take pains to give a
statute a limiting construction in order to avoid a constitutional
difficulty.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As we now explain, we decline the government's invitation to construe the
FDCA's misbranding provisions to criminalize the simple promotion of a
drug's off-label use by pharmaceutical manufacturers and their
representatives because such a construction &mdash; and a conviction obtained
under the government's application of the FDCA &mdash; would run afoul of the
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>A. Applicable <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X10V1PA003?jcsearch=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> Doctrine</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The First Amendment protects against government regulation and suppression
<span CLASS="page_no" data-cite="703 f 3d 163" data-cite-type="PrimaryFederalReporter" data-cite-pageno="163" data-primary-citation="703 F.3d 149">[*163]</span> 
of speech on account of its content. <i>Turner Broad. System, Inc. v. F.C.C.</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">512 U.S. 622</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">641-42</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=114%20supreme%20court%202445&amp;summary=yes#jcite">114 S.Ct. 2445</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCKG?jcsearch=129%20l%20ed%202d%20497&amp;summary=yes#jcite">129 L.Ed.2d 497</a> (1994); <i>see Ward v.</i>
<i>Rock Against Racism</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBR0?jcsearch=491%20us%20781&amp;summary=yes#jcite">491 U.S. 781</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBR0?jcsearch=491%20us%20781&amp;summary=yes#jcite">791</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=109%20supreme%20court%202746&amp;summary=yes#jcite">109 S.Ct. 2746</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBR0?jcsearch=105%20l%20ed%202d%20661&amp;summary=yes#jcite">105 L.Ed.2d 661</a>
(1989); <i>R.A.V. v. City of St. Paul</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC6S?jcsearch=505%20us%20377&amp;summary=yes#jcite">505 U.S. 377</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC6S?jcsearch=505%20us%20377&amp;summary=yes#jcite">386</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=112%20supreme%20court%202538&amp;summary=yes#jcite">112 S.Ct. 2538</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC6S?jcsearch=120%20l%20ed%202d%20305&amp;summary=yes#jcite">120 L.Ed.2d 305</a> (1992). Content-based speech restrictions are subject to
"strict scrutiny" &mdash; that is, the government must show that the regulation at
issue is narrowly tailored to serve or promote a compelling government
interest. <i>See Brown v. Entm't Merchs. Ass'n</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FKH0E003?jcsearch=131%20supreme%20court%202729&amp;summary=yes#jcite">131 S.Ct. 2729</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FKH0E003?jcsearch=131%20supreme%20court%202729&amp;summary=yes#jcite">2738</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FKH0E003?jcsearch=180%20l%20ed%202d%20708&amp;summary=yes#jcite">180 L.Ed.2d 708</a> (2011) (citing <i>R.A.V.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC6S?jcsearch=505%20us%20377&amp;summary=yes#jcite">505 U.S. at 395</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=112%20supreme%20court%202538&amp;summary=yes#jcite">112 S.Ct. 2538</a>). Content-based government regulations are "presumptively
invalid." <i>R.A.V.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC6S?jcsearch=505%20us%20377&amp;summary=yes#jcite">505 U.S. at 382</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=112%20supreme%20court%202538&amp;summary=yes#jcite">112 S.Ct. 2538</a>. Meanwhile,
non-content-based regulation and regulation of commercial speech &mdash;
expression solely related to the economic interests of the speaker and its
audience &mdash; are subject to intermediate scrutiny. <i>See Turner Broad.</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">512 U.S. at 642</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=114%20supreme%20court%202445&amp;summary=yes#jcite">114 S.Ct. 2445</a>; <i>Cent. Hudson Gas &amp; Elec. Corp. v. Pub.</i>
<i>Serv. Comm'n of N.Y.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. 557</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">563-64</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=65%20l%20ed%202d%20341&amp;summary=yes#jcite">65 L.Ed.2d 341</a>
(1980). Criminal regulatory schemes, moreover, warrant even more careful
scrutiny. <i>See Holder v. Humanitarian Law Project</i>, <cite>___ U.S. ___</cite>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=130%20supreme%20court%202705&amp;summary=yes#jcite">130 S.Ct. 2705</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=130%20supreme%20court%202705&amp;summary=yes#jcite">2724</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=177%20l%20ed%202d%20355&amp;summary=yes#jcite">177 L.Ed.2d 355</a> (2010) (applying more rigorous
scrutiny); <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=130%20S.%20Ct.%202734&amp;summary=yes#jcite">id. at 2734</a> (Breyer, J., dissenting) ("It is not surprising that
the majority, in determining the constitutionality of criminally prohibiting
the plaintiffs' proposed activities, would apply . . . a more demanding
standard. Indeed, where, as here, a statute applies criminal penalties . . .
I should think we would scrutinize the statute and justifications strictly."
(internal quotation marks and citations omitted) (citing cases)); <i>see also</i>
<i>City of Houston v. Hill</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBG9?jcsearch=482%20us%20451&amp;summary=yes#jcite">482 U.S. 451</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBG9?jcsearch=482%20us%20451&amp;summary=yes#jcite">459</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=107%20supreme%20court%202502&amp;summary=yes#jcite">107 S.Ct. 2502</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBG9?jcsearch=96%20l%20ed%202d%20398&amp;summary=yes#jcite">96 L.Ed.2d 398</a>
(1987) ("Criminal statutes must be scrutinized with particular care."
(<span CLASS="page_no" data-cite="2012 bl 316528 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> internal citations omitted)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In applying these principles, we have a benefit not available to the
district court: the Supreme Court's decision in <i>Sorrell v. IMS Health, Inc.</i>,
<cite>___ U.S. ___</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a> (2011), a case involving
speech restrictions on pharmaceutical marketing. In <i>Sorrell</i>, the Vermont
Prescription Confidentiality Law (the "VPCL") prohibited pharmaceutical
companies and similar entities from using prescriber-identifying information
for marketing purposes; it was challenged on First Amendment grounds. <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id. at
2661-62</a>; <i>see also</i> Vt. Stat. Ann., Tit. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X17BOQI003?jcsearch=18%20V.S.A.%20%204631(e)(4)&amp;summary=yes#jcite">18 &sect; 4631</a>(e)(4).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The <i>Sorrell</i> Court held that "[s]peech in aid of pharmaceutical marketing .
. . is a form of expression protected by the . . . <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a>. . . .
[The] creation and dissemination of information are speech within the
meaning of the [Constitution]." <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id. at 2659</a>, 2667. The Court held that the
Vermont statute set forth content- and speaker-based restrictions, and that
the statute was therefore subject to heightened scrutiny. <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id. at 2662-65</a>.
Because the VPCL disfavored speech with a particular content (marketing)
when expressed by certain disfavored speakers (pharmaceutical
manufacturers), the Court held that it unconstitutionally restricted speech.
<i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id. at 2662-65</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=2672&amp;summary=yes#jcite">2672</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In reaching this conclusion, <i>Sorrell</i> engaged in a two-step inquiry. First,
the Court considered whether the government regulation restricting speech
was content- and speaker-based. <i>See </i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">id. at 2662-64</a>. The Court held that it
was; the regulation was therefore subject to heightened scrutiny and was
"presumptively invalid." <i>See <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">id</a>.</i> Second, the Court considered whether the
government had shown that the restriction on speech was consistent
<span CLASS="page_no" data-cite="703 f 3d 164" data-cite-type="PrimaryFederalReporter" data-cite-pageno="164" data-primary-citation="703 F.3d 149">[*164]</span> 
with the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> under the applicable level of heightened scrutiny.
<i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id. at 2663</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=2667-68&amp;summary=yes#jcite">2667-68</a>. The Court did not decide the level of heightened
scrutiny to be applied, that is, strict, intermediate, or some other form of
heightened scrutiny. <i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id</a>.</i> Rather, after observing that "[i]n the ordinary
case, it is all but dispositive to conclude that a law is content-based,"
the Court concluded that the Vermont statute was unconstitutional even under
the lesser intermediate standard set forth in <i>Central Hudson. </i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id. at 2667</a>;
<i>see Cent. Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. The Court further
observed that the "outcome is the same whether a special commercial speech
inquiry or a stricter form of judicial scrutiny is applied." <i>Sorrell</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2667</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In considering whether the government had shown that the restriction on
speech was consistent with the First Amendment, the <i>Sonell</i> Court turned to
<i>Central Hudson. See id.</i> at 2667-68. <i>Central Hudson</i> sets forth a four-part
test to determine whether commercial speech is protected by the First
Amendment. <i>Cent. Hudson</i>, 447 U.S: at 566, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. First, as a
threshold matter, to warrant <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.amend.%20I&amp;summary=yes#jcite">First Amendment</a> protection, the speech in
question must not be misleading and must concern lawful activity. <i>Id.; see</i>
<i>infra</i> note 11 and accompanying text. Second, to justify regulations
restricting speech, the asserted government interest must be substantial.
<i>Id.</i> Third, the regulation must directly advance the governmental interest
asserted, <i>id.</i>, "to a material degree," &pound;4 <i>Liquormart, <span CLASS="page_no" data-cite="2012 bl 316528 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> Inc. v. Rhode Island</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">517 U.S. 484</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">505</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=116%20supreme%20court%201495&amp;summary=yes#jcite">116 S.Ct. 1495</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=134%20l%20ed%202d%20711&amp;summary=yes#jcite">134 L.Ed.2d 711</a> (1996) (quoting <i>Edenfield</i>
<i>v. Fane</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">507 U.S. 761</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">771</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2NVFN?jcsearch=123%20l%20ed%202d%20543&amp;summary=yes#jcite">123 L.Ed.2d 543</a> (1993)). "[A]
commercial speech regulation`may not be sustained if it provides only
ineffective or remote support for the government's purpose.'" <i>Liquormart</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">517 U.S. at 505</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=116%20supreme%20court%201495&amp;summary=yes#jcite">116 S.Ct. 1495</a> (quoting <i>Cent</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 564</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>). Fourth, the regulation must be "narrowly drawn," and may
not be more extensive than necessary to serve the interest, <i>Cent. Hudson</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 565-66</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>; see also <i>Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2667-69</a>
(citing <i>Bd. of Tr. of State Univ. of N.Y. v. Fox</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBQI?jcsearch=492%20us%20469&amp;summary=yes#jcite">492 U.S. 469</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBQI?jcsearch=492%20us%20469&amp;summary=yes#jcite">480-81</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBQI?jcsearch=109%20supreme%20court%203028&amp;summary=yes#jcite">109 S.Ct. 3028</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBQI?jcsearch=106%20l%20ed%202d%20388&amp;summary=yes#jcite">106 L.Ed.2d 388</a> (1989)); <i>Thompson v. W. States Med. Ctr.</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. 357</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">374</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=152%20l%20ed%202d%20563&amp;summary=yes#jcite">152 L.Ed.2d 563</a> (2002). The government
cannot "completely suppress information when narrower restrictions on
expression would serve its interests as well." <i>Cent. Hudson</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 565</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. "Under the commercial speech inquiry, it is
the [government's] burden to justify its content-based law as consistent
with the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a>." <i>Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2667</a> (citing <i>Thompson</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 373</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>B. Application</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In prosecuting Caronia, the government construed the FDCA's misbranding
provisions to prohibit and criminalize the promotion of off-label drug use.
We review the government's theory of prosecution under the <i>Sorrell</i> Court's
two-step analysis to determine whether it runs afoul of the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a>.
First, we conclude that the government's construction of the FDCA's
misbranding provisions imposes content- and speaker-based restrictions on
speech subject to heightened scrutiny. Second, we conclude the government
cannot justify a criminal prohibition of off-label promotion even under
<i>Central Hudson's</i> less rigorous intermediate test.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>1. Heightened Scrutiny</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government's construction of the FDCA's misbranding provisions to
prohibit and criminalize the promotion of off-label drug use by
pharmaceutical manufacturers
<span CLASS="page_no" data-cite="703 f 3d 165" data-cite-type="PrimaryFederalReporter" data-cite-pageno="165" data-primary-citation="703 F.3d 149">[*165]</span> 
is content- and speaker-based, and, therefore, subject to heightened
scrutiny. <i>See <cite>id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, the government's interpretation of the FDCA's misbranding
provisions to prohibit off-label promotion is content-based because it
distinguishes between "favored speech" and "disfavored speech on the basis
of the ideas or views expressed." <i>See Turner Broad.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">512 U.S. at 643</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=114%20supreme%20court%202445&amp;summary=yes#jcite">114 S.Ct. 2445</a>; <i>accord Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2663</a>. Under this construction,
speech about the government-approved use of drugs is permitted, while
certain speech about the off-label use of drugs &mdash; that is, uses not approved
by the government &mdash; is prohibited, even though the off-label use itself is
not. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a), <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)(2)&amp;summary=yes#jcite">333</a>(a)(2). Indeed, the content of the regulated
speech drives this construction of the FDCA; as in <i>Sorrell</i>, the "express
purpose and practical effect" of the government's ban on promotion is to
"diminish the effectiveness of [off-label drug] marketing by manufacturers."
<i>See Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2663</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, this construction is speaker-based because it targets one kind of
speaker &mdash; pharmaceutical manufacturers &mdash; while allowing others to speak
without restriction. <i>See </i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">id. at 2663</a>. In <i>Sorrell</i>, pharmaceutical companies
were barred from obtaining and using prescriber-identifying information for
marketing purposes, but a wide range of other speakers, including private
and academic researchers, could acquire and use the information. <i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id</a>.</i>
Similarly, here, because off-label prescriptions and drug use are legal, the
government's application of the FDCA permits <span CLASS="page_no" data-cite="2012 bl 316528 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> physicians and academics, for
example, to speak about off-label use without consequence, while the same
speech is prohibited when delivered by pharmaceutical manufacturers.
<i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a), <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)&amp;summary=yes#jcite">333</a>(a). This construction "thus has the effect of
preventing [pharmaceutical manufacturers] &mdash; and only [pharmaceutical
manufacturers] &mdash; from communicating with physicians in an effective and
informative manner." <i>Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2663</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Additionally, a claim to First Amendment protection here is more
compelling than in <i>Sorrell</i> because this case involves a criminal regulatory
scheme subject to more careful scrutiny. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(a); <i>Humanitarian</i>
<i>Law Project</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=130%20supreme%20court%202705&amp;summary=yes#jcite">130 S.Ct. at 2724</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, the government's construction of the FDCA's misbranding
provisions to prohibit and criminalize off-label promotion is content- and
speaker-based, and subject to heightened scrutiny under <i>Sorrell.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>2. Central Hudson</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The first two prongs of <i>Central Hudson</i> are easily satisfied here. First,
promoting off-label drug use concerns lawful activity (off-label drug use),
and the promotion of off-label drug use is not in and of itself false or
misleading.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a>

<i>See <span CLASS="page_no" data-cite="703 f 3d 166" data-cite-type="PrimaryFederalReporter" data-cite-pageno="166" data-primary-citation="703 F.3d 149">[*166]</span> Cent. Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. Second, the government's
asserted interests in drug safety and public health are substantial. <i>See <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20U.S.%20557&amp;summary=yes#jcite">id</a>.</i>
Specifically, the government asserts an interest in preserving the
effectiveness and integrity of the FDCA's drug approval process, and an
interest in reducing patient exposure to unsafe and ineffective drugs. <i>See</i>
<i>FDA v. Brown &amp; Williamson Tobacco Corp.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. 120</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">133</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=146%20l%20ed%202d%20121&amp;summary=yes#jcite">146 L.Ed.2d 121</a> (2000) ("[O]ne of the [FDCA's] core objectives is to ensure
that any product regulated by the FDA is`safe' and`effective' for its
intended use.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The third and fourth prongs of <i>Central Hudson</i> require that the regulation
directly advance the government's interests and be narrowly drawn. <i>See Cent.</i>
<i>Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. We turn to the third and fourth
prongs below.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>a. Direct Advancement</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government's construction of the FDCA as prohibiting off-label
promotion does not, by itself, withstand scrutiny under <i>Central Hudson's</i>
third prong. First, off-label drug usage is not unlawful, and the FDA's drug
approval process generally contemplates that approved drugs will be used in
off-label ways. In effect, even if pharmaceutical manufacturers are barred
from off-label promotion, physicians can prescribe, and patients can use,
drugs for off-label purposes. <i>See supra</i> 152-54. As off-label drug use itself
is not prohibited, it does not follow that prohibiting the truthful
promotion of off-label drug usage by a particular class of speakers would
directly further the government's goals of preserving the efficacy and
integrity of the FDA's drug approval process and reducing patient exposure
to unsafe and ineffective drugs. <i>See Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2668-69</a> (holding
government interest in protecting physician privacy not directly served when
law made prescriber-identifying information available to "all but a narrow
class of disfavored speakers").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, prohibiting off-label promotion by a pharmaceutical manufacturer
while simultaneously allowing off-label use "paternalistically" interferes
with the ability of physicians and patients <span CLASS="page_no" data-cite="2012 bl 316528 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> to receive potentially relevant
treatment information; such barriers to information about off-label use
could inhibit, to the public's detriment, informed and intelligent treatment
decisions. <i>See Va. Bd. of Pharmacy v. Va. Citizens Consumer Council, Inc.</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">425 U.S. 748</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">770</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=96%20supreme%20court%201817&amp;summary=yes#jcite">96 S.Ct. 1817</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=48%20l%20ed%202d%20346&amp;summary=yes#jcite">48 L.Ed.2d 346</a> (1976) (discussing "highly
paternalistic approach" of government prohibitions on free flow of
information); <i>see also Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2670-72</a> ("`[The] fear that
[physicians, sophisticated and experienced customers,] would make bad
decisions if given truthful information' cannot justify content-based
burdens on speech.") (citing sources); <i>Liquormart</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">517 U.S. at 503</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=116%20supreme%20court%201495&amp;summary=yes#jcite">116 S.Ct. 1495</a> ("[B]ans against truthful, nonmisleading commercial speech .
. . usually rest solely on the offensive assumption that the public will
respond`irrationally' to the truth. . . . The <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.amend.%20I&amp;summary=yes#jcite">First Amendment</a> directs us to
be especially skeptical of regulations that seek to keep people in the dark
for what the government perceives to be their own good."). In fact, in
granting safe harbor to manufacturers by permitting the dissemination
<span CLASS="page_no" data-cite="703 f 3d 167" data-cite-type="PrimaryFederalReporter" data-cite-pageno="167" data-primary-citation="703 F.3d 149">[*167]</span> 
of off-label information through scientific journals, the FDA itself
"recognizes that public health can be served when health care professionals
receive truthful and non-misleading scientific and medical information on
unapproved uses" of approved drugs. Dep't of Health and Human Serv., Good
Reprint Practices, <i><cite>supra</cite></i>, at <b>III, V;</b><i>see Wash. Legal Found, v. Henney</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3IN8E?jcsearch=202%20f%203d%20331&amp;summary=yes#jcite">202 F.3d 331</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3IN8E?jcsearch=202%20f%203d%20331&amp;summary=yes#jcite">335</a> (D.C.Cir.2000) (discussing FDA "safe harbor," where
certain forums for off-label discussion, such as continuing medical
education programs and scientific publications, would not be used against
manufacturers in misbranding enforcement actions).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Here, as the FDA recognizes, it is the physician's role to consider
multiple factors, including a drug's FDA-approval status, to determine the
best course of action for her patient. <i>See</i> FDA Drug Bull., <i><cite>supra</cite></i>, at 5;
<i>Buckman</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4U3HP?jcsearch=531%20us%20341&amp;summary=yes#jcite">531 U.S. at 350</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=121%20supreme%20court%201012&amp;summary=yes#jcite">121 S.Ct. 1012</a>; <i>Weaver</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5402C?jcsearch=886%20f%202d%20194&amp;summary=yes#jcite">886 F.2d at 198-99</a>;
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X197660003?jcsearch=21%20usc%20396&amp;summary=yes#jcite">21 U.S.C. &sect; 396</a>; <i>see also Thompson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 367</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>
(discussing the "general rule" that "the speaker and the audience, not the
government, assess the value of the information presented") (quoting
<i>Edenfield</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">507 U.S. at 767</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>); <i>see also Va. Bd. of Pharmacy</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">425 U.S. at 770</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=96%20supreme%20court%201817&amp;summary=yes#jcite">96 S.Ct. 1817</a> ("[T]he choice . . . is not ours to make or
the [legislature's]."). While some off-label information could certainly be
misleading or unhelpful, this case does not involve false or misleading
promotion. <i>See <cite>supra</cite></i> note 11. Moreover, in the fields of medicine and public
health, "where information can save lives," it only furthers the public
interest to ensure that decisions about the use of prescription drugs,
including off-label usage, are intelligent and well-informed. <i>See Sorrell</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2664</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">2671</a>; <i>Thompson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 366</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a> (quoting
<i>Va. Bd. of Pharmacy</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">425 U.S. at 765</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=96%20supreme%20court%201817&amp;summary=yes#jcite">96 S.Ct. 1817</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government's construction of the FDCA essentially legalizes the
outcome &mdash; off-label use &mdash; but prohibits the free flow of information that
would inform that outcome. If the government's objective is to shepherd
physicians to prescribe drugs only on-label, criminalizing manufacturer
promotion of off-label use while permitting others to promote such use to
physicians is an indirect and questionably effective means to achieve that
goal. Thus, the government's construction of the FDCA's misbranding
provisions does not directly <span CLASS="page_no" data-cite="2012 bl 316528 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> advance its interest in reducing patient
exposure to off-label drugs or in preserving the efficacy of the FDA drug
approval process because the off-label use of such drugs continues to be
generally lawful. Accordingly, the government's prohibition of off-label
promotion by pharmaceutical manufacturers "provides only ineffective or
remote support for the government's purpose." <i>See Liquormart</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">517 U.S. at 504-05</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=116%20supreme%20court%201495&amp;summary=yes#jcite">116 S.Ct. 1495</a> (quoting <i>Cent. Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 564</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>b. Narrowly Drawn</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The last prong of <i>Central Hudson</i> requires the government's regulation to
be narrowly drawn to further the interests served. <i>Cent. Hudson</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. Here, the government's construction of the
FDCA to impose a complete and criminal ban on off-label promotion by
pharmaceutical manufacturers is more extensive than necessary to achieve the
government's substantial interests. <i>See <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20U.S.%20557&amp;summary=yes#jcite">id</a>.</i> Numerous, less
speech-restrictive alternatives are available, as are non-criminal
penalties. <i>See Thompson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 372-73</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To advance the integrity of the FDA's drug approval process and increase
the safety of off-label drug use, the government could pursue several
alternatives without excessive First Amendment restrictions.
<span CLASS="page_no" data-cite="703 f 3d 168" data-cite-type="PrimaryFederalReporter" data-cite-pageno="168" data-primary-citation="703 F.3d 149">[*168]</span> 
<i>See Cent. Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 564</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. For example, if the
government is concerned about the use of drugs off-label, it could more
directly address the issue. If the government is concerned that off-label
promotion may mislead physicians, it could guide physicians and patients in
differentiating between misleading and false promotion, exaggerations and
embellishments, and truthful or non-misleading information. <i>See Osborn, Can</i>
<i>I Tell You The Truth?, <cite>supra</cite></i>, at 306-07. The government could develop its
warning or disclaimer systems, or develop safety tiers within the off-label
market, to distinguish between drugs. <i>See</i> Coleen Klasmeier and Martin H.
Redish, <i>Off-Label Prescription Advertising, the FDA and the First Amendment:</i>
<i>A Study in the Values of Commercial Speech Protection</i>, <cite>37 Am. J.L. &amp; Med.
315</cite>, 334 (2011). The government could require pharmaceutical manufacturers
to list all applicable or intended indications when they first apply for FDA
approval, enabling physicians, the government, and patients to track a
drug's development. To minimize off-label use, or manufacturer evasion of
the approval process for such use, the government could create other limits,
including ceilings or caps on off-label prescriptions. The FDA could further
remind physicians and manufacturers of, and even perhaps further regulate,
the legal liability surrounding off-label promotion and treatment
decisions.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a> Finally, where off-label drug use is exceptionally
concerning, the government could prohibit the off-label use altogether. <i>See,</i>
<i>e.g., Bader</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1HKTUQ003?jcsearch=678%20f%203d%20858&amp;summary=yes#jcite">678 F.3d at 873-75</a> &amp; n. 10 (citing <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MG003?jcsearch=21%20U.S.C.%20%20333(e)&amp;summary=yes#jcite">21 U.S.C. &sect; 333</a>(e)
(prohibiting off-label use of human growth hormone)). The possibilities are
numerous indeed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "If the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> means anything, it means that regulating speech
must be a last &mdash; not first &mdash; resort." <i>Thompson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 373</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>. The government has not established a "reasonable fit" among
its interests in drug safety and public health, the lawfulness of off-label
use, and its construction of the FDCA to prohibit <span CLASS="page_no" data-cite="2012 bl 316528 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[**16]</span> off-label promotion. <i>See</i>
<i>Fox</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBQI?jcsearch=492%20us%20469&amp;summary=yes#jcite">492 U.S. at 480</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBQI?jcsearch=109%20supreme%20court%203028&amp;summary=yes#jcite">109 S.Ct. 3028</a>. The government's interests could be
sewed equally well by more limited and targeted restrictions on speech. <i>See</i>
<i>Cent. Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 565</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. The government contends that
these alternative means of reducing patient exposure to unsafe, untested
drugs and maintaining the integrity of the FDA-approval process are
"indefensible" (Gov't Br. 70), because they are not administrable, feasible,
or otherwise effective. In the absence of any support, such conclusory
assertions are insufficient to sustain the government's burden of
demonstrating that the proposed alternatives are less effective than its
proposed construction of the FDCA in furthering the government interests
identified. <i>See Ashcroft v. ACLU</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XRHSRFQNB5G0?jcsearch=542%20us%20656&amp;summary=yes#jcite">542 U.S. 656</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XRHSRFQNB5G0?jcsearch=542%20us%20656&amp;summary=yes#jcite">665</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XRHSRFQNB5G0?jcsearch=542%20us%20656&amp;summary=yes#jcite">669</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=124%20supreme%20court%202783&amp;summary=yes#jcite">124 S.Ct. 2783</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XRHSRFQNB5G0?jcsearch=159%20l%20ed%202d%20690&amp;summary=yes#jcite">159 L.Ed.2d 690</a> (2004).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, even if speech can be used as evidence of a drug's intended
use, we decline to adopt the government's construction of the FDCA's
misbranding provisions to prohibit manufacturer promotion alone as it would
unconstitutionally restrict free speech. We construe the misbranding
provisions of the FDCA as not prohibiting and criminalizing the truthful
off-label promotion of FDA-approved prescription drugs. Our conclusion is
limited
<span CLASS="page_no" data-cite="703 f 3d 169" data-cite-type="PrimaryFederalReporter" data-cite-pageno="169" data-primary-citation="703 F.3d 149">[*169]</span> 
to FDA-approved drugs for which off-label use is not prohibited, and we do
not hold, of course, that the FDA cannot regulate the marketing of
prescription drugs. We conclude simply that the government cannot prosecute
pharmaceutical manufacturers and their representatives under the FDCA for
speech promoting the lawful, off-label use of an FDA-approved drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>CONCLUSION</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the reasons set forth above, we VACATE the judgment of conviction and
REMAND the case to the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The FDCA provides: "No person shall introduce or deliver for
introduction into interstate commerce any new drug, unless an approval of an
application filed pursuant to subsection (b) or <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)&amp;summary=yes#jcite">(j)</a> of this section is
effective with respect to such drug." <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(a). A "new drug" is
defined as: "Any drug . . . not generally recognized . . . as safe and
effective for use under the conditions prescribed, recommended, or suggested
in the labeling thereof." <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5M2003?jcsearch=21%20U.S.C.%20%20321(p)&amp;summary=yes#jcite">21 U.S.C. &sect; 321</a>(p).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> <i>See also</i> James M. Beck &amp; Elizabeth D. Azari, <i>FDA, Off-Label Use, and</i>
<i>Informed Consent: Debunking Myths and Misconceptions</i>, 53 Food &amp; Drug L.J.
71, 76-77 (1998); <i>cf.</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X197660003?jcsearch=21%20usc%20396&amp;summary=yes#jcite">21 U.S.C. &sect; 396</a> (protecting physician authority to
prescribe or administer any legally-marketed device to patient).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> A drug is also misbranded if, <i>inter alia</i>: its label is false or
misleading; the label fails to display required information prominently; its
container is misleading; or it is dangerous to health when used in the
dosage, manner, frequency, or duration prescribed, recommended, or suggested
on the label. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(a)-<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(n)&amp;summary=yes#jcite">(n)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The facts are drawn primarily from the trial record. On appeal, this
Court must view the evidence in the light most favorable to the government,
drawing all reasonable inferences in its favor. <i>See United States v. Amico</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X172OFQ003?jcsearch=486%20f%203d%20764&amp;summary=yes#jcite">486 F.3d 764</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X172OFQ003?jcsearch=486%20f%203d%20764&amp;summary=yes#jcite">780</a> (2d Cir.2007).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> In December of 2011, the FDA released recommendations for the
pharmaceutical industry with respect to how manufacturers and their
representatives can respond to "unsolicited requests for off-label
information." <i>See generally</i> U.S. Food and Drug Administration, <i>Guidance for</i>
<i>Industry, Responding to Unsolicited Requests for Off-Label Information About</i>
<i>Prescription Drugs and Medical Devices</i> (2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> The government's summation and rebuttal include numerous additional
examples of the government's assertion that Caronia was guilty because he
conspired to promote and market Xyrem for unapproved uses. (<i>See, e.g.</i>, Trial
Tr. 834 ("On November 2nd . . . Gleason, comes in to pitch to [Charno] and
he right away goes off-label, promotes and markets Xyrem for uses that are
not approved by the FDA, clear as a bell."); <i><cite>id</cite>.</i> ("[Caronia is] misbranding.
He's promoting a drug, Xyrem, that's dangerous for unapproved uses."); <i></i><cite>id.
at 836</cite> ("[H]e crossed the line and here's the labeling and you can only
promote Xyrem for cataplexy associated with narcolepsy and you can't do it
for anything else."); <i></i><cite>id. at 847</cite> ("The conspiracy is promoting it and then
trying to persuade through off-label communications to get Charno to write
prescriptions off-label"); <i></i><cite>id. at 883</cite> ("And the facts are one prong the drug
was promoted for unapproved uses in a meeting with Charno on the 26th of
October and the 2nd of November with the expectation or with the effort or
with the attempt or with the conspiracy that by promoting it for off-label
use, Charno would write a prescription and cause the drug to be shipped from
St. Louis to some patient out of state."); <i>see also </i><cite>id. at 821-22</cite>, 827, 829,
840-43, 847-48, 872-74, 878).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Caronia also argues that the verdict sheet was improperly phrased and
the jury's verdict was inconsistent. In light of our disposition of the
First Amendment issue, we need not reach these issues.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> <i>See Wisconsin v. Mitchell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. 476</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">489</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=124%20l%20ed%202d%20436&amp;summary=yes#jcite">124 L.Ed.2d 436</a> (1993) (concluding First Amendment "does not prohibit the
use of speech to establish . . . intent"); <i>Whitaker v. Thompson</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20f%203d%20947&amp;summary=yes#jcite">353 F.3d 947</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20f%203d%20947&amp;summary=yes#jcite">953</a> (D.C.Cir.2004) (holding product's labeling may be used to
infer its intended use and, thus, whether it is an unapproved drug under
FDCA).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> Although we assume, without deciding, that such use of evidence of
speech is permissible under <i>Mitchell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. 476</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a>, we
observe that it still remains unclear how the government would identify
criminal misbranding from communications between drug manufacturers and
physicians authorized to prescribe drugs for off-label use. For example,
would a manufacturer be guilty of misbranding if it ships Xyrem to a doctor
who, in placing his order, reveals that he prescribes the drug for off-label
use &mdash; on a theory that the manufacturer now knows that the drug is not
properly labeled for that use &mdash; but not if the manufacturer ships to a
doctor who does not reveal that he prescribes the drug off-label? Because
this case does not present us with that circumstance or others that might
raise questions about the scope of the misbranding proscription, we need not
address them here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> In <i>Whitaker</i>, cited by the dissent (Diss. Op. 14), the D.C. Circuit
held that the labeling of a product, which was not approved by the FDA as a
drug, constituted speech about unlawful activities and therefore did not
enjoy First Amendment protection because it was unlawful to sell an
unapproved product pursuant to claims about disease treatment. <i>See Whitaker</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20f%203d%20947&amp;summary=yes#jcite">353 F.3d at 953</a>. The government does not contend that off-label promotion is
in and of itself false or misleading. Of course, off-label promotion that is
false or misleading is not entitled to First Amendment protection. <i>See Cent.</i>
<i>Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. Under <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a), a
defendant may be prosecuted for untruthfully promoting the off-label use of
an FDA-approved drug, <i>e.g.</i>, making false or misleading statements about a
drug. The government did not argue at trial, nor does it argue on appeal,
that the promotion in question was false or misleading. (<i>See</i> Trial Tr. 823
(mentioning, in government's summation, that Caronia "did not give accurate
and complete information in promoting and marketing Xyrem," but focusing on
promotion as misbranding and not pursuing argument that speech was false or
misleading); Gov't Br. 58 (considering whether "the commercial speech in
question clears [the] hurdle" of <i>Central Hudson's</i> first prong, but not
contending that the speech concerns unlawful activity or is false or
misleading)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> Physicians and pharmaceutical manufacturers can be held accountable
for off-label drug use through medical malpractice and negligence theories
of liability. <i>See generally Boyle v. Revici</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3INK5?jcsearch=961%20f%202d%201060&amp;summary=yes#jcite">961 F.2d 1060</a> (2d Cir.1992);
<i>Sita v. Danek Med. Inc.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4FHGJ?jcsearch=43%20f%20supp%202d%20245&amp;summary=yes#jcite">43 F.Supp.2d 245</a> (E.D.N.Y.1999); <i>Retkwa v.</i>
<i>Orentreich</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XFNE8C?jcsearch=154%20new%20york%20misc%202d%20164&amp;summary=yes#jcite">154 Misc.2d 164</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XFNE8C?jcsearch=584%20new%20york%20supplement%202d%20710&amp;summary=yes#jcite">584 N.Y.S.2d 710</a> (N.Y.Sup.Ct.1992).
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DEBRA ANN LIVINGSTON, Circuit Judge, dissenting:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alfred Caronia was convicted of conspiring to introduce a prescription
drug into interstate commerce with the intent that it be used in ways its
labeling neither disclosed nor described. This intent was revealed, <i>inter</i>
<i>alia</i>, through his speech. Because the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> has never prohibited
the government from using speech as evidence of motive or intent, <i>see</i>
<i>Wisconsin v. Mitchell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. 476</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">489</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=124%20l%20ed%202d%20436&amp;summary=yes#jcite">124 L.Ed.2d 436</a>
(1993), I would affirm Caronia's conviction. By holding, instead, that
Caronia's conviction must be vacated &mdash; and on the theory that whatever the
elements of the crime for which he was duly tried, he was in fact convicted
for promoting a drug for unapproved uses, in supposed violation of the First
Amendment &mdash; the majority calls into question the very foundations of our
century-old system of drug regulation. I do not believe that the Supreme
Court's precedents compel such a result. I therefore respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>I. Intended Uses</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alfred Caronia was convicted of conspiring to introduce a "misbranded"
drug into interstate commerce. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEHRNC003?jcsearch=18%20usc%20371&amp;summary=yes#jcite">18 U.S.C. &sect; 371</a>; <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a). Under
the Federal Food, Drug and Cosmetic Act ("FDCA"), one way in which a drug is
misbranded is if its labeling lacks adequate directions for layperson use.
<i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(f)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(f)(1); <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20cfr%20201%205&amp;summary=yes#jcite">21 C.F.R. &sect; 201.5</a>. Whether a drug's directions are
"adequate . . . for use" depends on the drug's intended uses. This is
because the Food and Drug Administration ("FDA") defines "adequate
directions for use" as "directions under which <span CLASS="page_no" data-cite="2012 bl 316528 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[**17]</span> the layman can use a drug
safely and <i>for the purposes for which it is intended</i>" <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20cfr%20201%205&amp;summary=yes#jcite">21 C.F.R. &sect; 201.5</a>
(emphasis added). Directions are adequate only if they include, for example,
"[s]tatements of all . . . uses for which such drug is intended," and "usual
quantities [of dose] for each of the uses for which it is intended."
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20C.F.R.%20%20201.5(a)&amp;summary=yes#jcite">21 C.F.R. &sect; 201.5</a>(a), <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ47G003?jcsearch=21%20C.F.R.%20%20201.5(b)&amp;summary=yes#jcite">(b)</a>. This labeling provision is in part merely a
disclosure requirement for the benefit of a drug's lay users. But some uses
of drugs are never safe, at least for a layperson; because it is impossible
to provide adequate directions for such uses, this provision also
effectively prohibits introducing drugs into interstate commerce with the
intent that the drugs be used in ways that are unsafe for laypersons.<span CLASS="page_no" data-cite="703 f 3d 170" data-cite-type="PrimaryFederalReporter" data-cite-pageno="170" data-primary-citation="703 F.3d 149">[*170]</span> <a HREF="#fn101" name="fnref_fn101">[fn1]</a>

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The labeling on the drug at issue in this case, Xyrem, stated that it was
"indicated for the treatment of excessive daytime sleepiness and cataplexy
in patients with narcolepsy." At all relevant times, the FDA had not
approved Xyrem for any other Uses. Xyrem's labeling did not state any other
intended uses for the drug, nor provide directions for any other intended
uses. Unsurprisingly, then, Caronia did not argue before the jury that
Xyrem's labeling included adequate directions for the off-label uses that he
was alleged to have promoted. Rather, his trial focused on whether Caronia
agreed with his employer, Orphan Medical, Inc. ("Orphan"), and with others
associated with Orphan, that Xyrem would be distributed for off-label use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Determining a product's "intended uses" has long been a central concern of
food and drug law. The concept originated in the Pure Food and Drugs Act of
1906, Pub.L. No. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=USACTS%2059-384&amp;summary=yes#jcite">59-384</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=34%20stat%20768&amp;summary=yes#jcite">34 Stat. 768</a>, which prohibited introducing any
adulterated or misbranded drug into interstate commerce, <i><cite>id</cite>.</i> <cite>&sect; 2</cite>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=34%20stat%20768&amp;summary=yes#jcite">34 Stat, at 768</a>, and which defined "drug" to include "any substance or
mixture of substances <i>intended</i> to be used for the cure, mitigation, or
prevention of disease," <i><cite>id</cite>.</i> <cite>&sect; 5</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=34%20stat%20768&amp;summary=yes#jcite">34 Stat, at 769</a> (emphasis added). Courts
found violations of that statute where, as in this manufacturer's speech
demonstrated an intended use that brought it within the scope of the statute
such that its label was required affirmatively to disclose certain
information. <i>See, e.g., United States v. Eleven Cartons of Drug Labeled in</i>
<i>Part "Vapex</i>," <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3IHGB?jcsearch=59%20f%202d%20446&amp;summary=yes#jcite">59 F.2d 446</a> (D.Md.1932) (holding that "Vapex" was "intended to
be used for the cure, mitigation or prevention of disease," and was thus a
"drug," because its label stated that it was "effective to relieve a head
cold instantly," <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3IHGB?jcsearch=59%20F.2d%20446&amp;summary=yes#jcite">id. at 447</a>; and further holding that the drug was
misbranded, even "assum[ing] that the inhalation of Vapex is innocuous,"
because it was "required to contain a declaration on the label of the
alcoholic content" yet failed to do so, <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3IHGB?jcsearch=59%20F.2d%20446&amp;summary=yes#jcite">id. at 449</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  When Congress expanded the law three decades later in the Food, Drug, and
Cosmetic Act of 1938, Pub.L. No. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=USACTS%2075-717&amp;summary=yes#jcite">75-717</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=52%20stat%201040&amp;summary=yes#jcite">52 Stat. 1040</a>, its revisions
remained anchored to the concept of "intended uses." The definition of
"drug" was broadened to also include "articles . . . <i>intended</i> to affect the
structure or any function of the body," <i><cite>id</cite>.</i> <cite>&sect; 201(g)(3)</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=52%20stat%201040&amp;summary=yes#jcite">52 Stat, at 1041</a>
(emphasis added), and the parallel category of "devices" was created and
similarly defined in terms of intended uses, <i>see <cite>id</cite>.</i> <cite>&sect; 201(h)</cite>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=52%20stat%201040&amp;summary=yes#jcite">52 Stat, at 1041</a>. At the same time, Congress broadened the definition <span CLASS="page_no" data-cite="2012 bl 316528 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[**18]</span> of a
"misbranded" drug to include any drug with labeling not bearing "adequate
directions for use." <i><cite>Id</cite>.</i> <cite>&sect; 502(f)(1)</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=52%20stat%201040&amp;summary=yes#jcite">52 Stat, at 1051</a>. Under the 1938 Act,
courts upheld convictions for introducing drugs into interstate commerce
that lacked adequate labeling for their intended uses, and routinely relied
on "oral representations made by . . . authorized sales distributors" to
determine a product's intended uses. <i>V.E. Irons, Inc. v. United States</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3RPPV?jcsearch=244%20f%202d%2034&amp;summary=yes#jcite">244 F.2d 34</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3RPPV?jcsearch=244%20f%202d%2034&amp;summary=yes#jcite">44</a> (1st Cir.1957) (upholding a conviction for introducing into
interstate commerce "articles of drug [that] were misbranded in that their
labeling failed to bear`adequate directions for use' for the various
diseases and conditions for which they were intended," and relying on "both
graphic materials distributed and testimony of oral representations to users
and prospective users. . . . show[ing] that the products shipped were to be
used as drugs").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The modern FDCA continues to define "drugs" (and "devices") on the basis
of an article's intended uses. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5M2003?jcsearch=21%20U.S.C.%20%20321(g)(1)(B)&amp;summary=yes#jcite">21 U.S.C. &sect; 321</a>(g)(1)(B), <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5M2003?jcsearch=21%20U.S.C.%20%20321(g)(1)(C)&amp;summary=yes#jcite">(C)</a>;
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5M2003?jcsearch=21%20U.S.C.%20%20321(h)(2)&amp;summary=yes#jcite">21 U.S.C. &sect; 321</a>(h)(2), <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5M2003?jcsearch=21%20U.S.C.%20%20321(h)(3)&amp;summary=yes#jcite">(3)</a>. The concept of "intended uses" therefore largely
defines the scope of the FDA's
<span CLASS="page_no" data-cite="703 f 3d 171" data-cite-type="PrimaryFederalReporter" data-cite-pageno="171" data-primary-citation="703 F.3d 149">[*171]</span> 
regulatory authority. <i>See FDA v. Brown &amp; Williamson Tobacco Corp.</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. 120</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">126</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=146%20l%20ed%202d%20121&amp;summary=yes#jcite">146 L.Ed.2d 121</a> (2000). To put the matter
in practical terms: it is because of the "intended uses" principle that
hardware stores are generally free to sell bottles of turpentine, but may
not label those bottles, "Hamlin's Wizard Oil: There is no Sore it will Not
Heal, No Pain it will not Subdue."<a HREF="#fn201" name="fnref_fn201">[fn2]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  According to regulations that have remained essentially unchanged for
sixty years, <i>see</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=17%20federal%20register%206818&amp;summary=yes#jcite">17 Fed.Reg. 6818</a>, 6820 (1952) (codified at
<cite>21 C.F.R. &sect; 1.106(o)</cite> (Cm.Supp.1955)), the FDA defines a drug's "intended
uses" on an objective, rather than subjective, basis:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The words intended uses or words of similar import . . . refer to
    the objective intent of the persons legally responsible for the
    labeling of drugs. The intent is determined by such persons'
    expressions or may be shown by the circumstances surrounding the
    distribution of the article. This objective intent may, for example,
    be shown by labeling claims, advertising matter, or oral or written
    statements by such persons or their representatives. It may be shown
    by the circumstances that the article is, with the knowledge of such
    persons or their representatives, offered and used for a purpose for
    which it is neither labeled nor advertised. . . . [I]f a
    manufacturer knows, or has knowledge of facts that would give him
    notice, that a drug introduced into interstate commerce by him is to
    be used for conditions, purposes, or uses other than the ones for
    which he offers it, he is required to provide adequate labeling for
    such a drug which accords with such other uses to which the article
    is to be put.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ49S003?jcsearch=21%20cfr%20201%20128&amp;summary=yes#jcite">21 C.F.R. &sect; 201.128</a>. As previously noted, Caronia did not contend at trial
that Xyrem's label (which provided dosage and other instructions for Xyrem's
use in the treatment of narcolepsy patients who experience cataplexy and
excessive daytime sleepiness) provided adequate instructions for any other
use. In this case, then, Xyrem was "misbranded" &mdash; and Caronia could be
guilty of conspiring with others to introduce it into interstate commerce in
such a state &mdash; if the conduct and statements of <span CLASS="page_no" data-cite="2012 bl 316528 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[**19]</span> the persons legally
responsible for labeling the drug (or the conduct and statements of their
representatives) demonstrated an objective intent that Xyrem be used for
off-label purposes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>II. The <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X10V1PA003?jcsearch=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> and Speech as Evidence of Intent</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is well settled that "[t]he First Amendment . . . does not prohibit the
evidentiary use of speech to establish the elements of a crime or to prove
motive or intent." <i>Wisconsin v. Mitchell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. 476</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">489</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=124%20l%20ed%202d%20436&amp;summary=yes#jcite">124 L.Ed.2d 436</a> (1993). To demonstrate that Xyrem was intended for off-label
uses (and thus that it was misbranded) the prosecution in this case relied,
<i>inter alia</i>, upon Caronia's statements that Xyrem could be used to treat
"insomnia, [f]ibromyalgia[,] periodic leg movement, restless leg, . . .
Parkin

son's <span CLASS="page_no" data-cite="703 f 3d 172" data-cite-type="PrimaryFederalReporter" data-cite-pageno="172" data-primary-citation="703 F.3d 149">[*172]</span> and . . . MS."<a HREF="#fn301" name="fnref_fn301">[fn3]</a> Because Caronia's speech was used simply as
evidence of Xyrem's intended uses, I agree with the government that
Caronia's conviction does not run afoul of the First Amendment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority unsurprisingly agrees that speech may be used as evidence of
intent. It even leaves open the possibility that speech may serve as
evidence of intent to introduce a misbranded drug into interstate commerce.
<i>See</i> Maj. Op. at 161. The majority nonetheless concludes that in this
particular case "the government clearly prosecuted Caronia for his words &mdash;
for his speech" and not for conspiring to introduce a misbranded drug into
interstate commerce. Maj. Op. at 161. I disagree that the government
prosecuted Caronia for his speech. I also fail to see how the majority's
reasoning would ever allow such speech to support a conviction under
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a). For this reason, I conclude the majority's opinion is
fundamentally at odds both with <i>Mitchell</i> and with the underlying premises
behind much of the FDCA's regulatory scheme.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I do not agree with the majority that Caronia was "prosecuted and
convicted for promoting Xyrem off-label." Maj. Op. at 161. The district
court correctly instructed the jury as to all the elements necessary to
prove a conspiracy, as well as the additional elements, derived from
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a), to prove the conspiracy's unlawful purpose:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      To sustain the charge of conspiracy to introduce into interstate
    commerce a misbranded drug, the Government must prove the element[s]
    of conspiracy as I previously described them for you and must also
    prove the following elements of misbranding through the introduction
    of a misbranded drug into interstate commerce.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      First, the Government must prove that the defendant conspired to
    introduce or conspired to cause to be introduced a drug into
    interstate commerce or conspired to deliver a drug for introduction
    into interstate commerce or conspired to cause a drug to be
    delivered for introduction into interstate commerce.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Second, the Government must prove that the drug was misbranded, as
    I've previously defined that term.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      If you find that the Government has satisfied its burden with
    respect to each of these elements, along with satisfying the
    elements of conspiracy as I have previously explained them to you,
    then you should find the defendant guilty of that prong of the
    conspiracy count charging him with conspiracy <span CLASS="page_no" data-cite="2012 bl 316528 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[**20]</span> to misbrand in
    violation of <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">Section 331(a)</a>.
<span CLASS="page_no" data-cite="703 f 3d 173" data-cite-type="PrimaryFederalReporter" data-cite-pageno="173" data-primary-citation="703 F.3d 149">[*173]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority makes much of the fact that the district court also
instructed the jury that "[a] misbranded drug may be shown by a promotion of
the drug by a distributor for an intended use different from the use for
which the drug was approved by the Food and Drug Administration." But this
wholly appropriate charge was but part of the district court's explanation
of the "objective intent" standard with respect to "intended uses":
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The intended use of a drug can be determined from its label,
    accompanying labels, promotional material, advertising or any other
    relevant source that reveals the manner in which the drug's
    distributors expect[] the product to be used. A misbranded drug may
    be shown by a promotion of the drug by a distributor for an intended
    use different from the use for which the drug was approved by the
    Food and Drug Administration, the Government agency charged with the
    responsibility for approving a drug's use. Under 21 Code of Federal
    Regulations, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ49S003?jcsearch=21%20C.F.R.%20%20201.128&amp;summary=yes#jcite">Section 201.128</a>, intended use or words of a similar
    import refer to the objective intent of the persons legally
    responsible for the labeling of drugs. The intent is determined by
    such persons' expressions or may be shown by the circumstances
    surrounding the distribution of the drug. This objective intent may,
    for example, be shown by labeling claims, advertising matter or oral
    or written statements by such persons or their representatives. It
    may be shown by the circumstances that the drug is, with the
    knowledge of such persons or their representatives, offered and used
    for a purpose for which it is neither labeled, nor advertised.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Granted, in a single sentence at the conclusion of this instruction the
district court stated that drug manufacturers "are not permitted to promote
uses for a drug that have not been cleared by the United States Food and
Drug Administration." In context, however, the district court was simply
instructing the jury that promotion of an off-label use may demonstrate an
objective intent that a drug be used for off-label purposes &mdash; and thus that
it is being placed into interstate commerce without proper labeling. And
this, contrary to the majority's suggestion, was not error.<a HREF="#fn401" name="fnref_fn401">[fn4]</a><i>See United</i>
<i>States v. Sabhnani</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1CSTPC003?jcsearch=599%20f%203d%20215&amp;summary=yes#jcite">599 F.3d 215</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1CSTPC003?jcsearch=599%20f%203d%20215&amp;summary=yes#jcite">237</a> (2d Cir.2010) (admonishing that jury
instructions are not to be read in isolation, but in their entirety, to
determine whether they communicate the "essential ideas" to the jury);
<i>accord United States v. Tran</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X18K696003?jcsearch=519%20f%203d%2098&amp;summary=yes#jcite">519 F.3d 98</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X18K696003?jcsearch=519%20f%203d%2098&amp;summary=yes#jcite">105</a> (2d Cir.2008); <i>see also Cupp</i>
<i>v. Naughten</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8KB?jcsearch=414%20us%20141&amp;summary=yes#jcite">414 U.S. 141</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8KB?jcsearch=414%20us%20141&amp;summary=yes#jcite">146-47</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=94%20supreme%20court%20396&amp;summary=yes#jcite">94 S.Ct. 396</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C8KB?jcsearch=38%20l%20ed%202d%20368&amp;summary=yes#jcite">38 L.Ed.2d 368</a> (<span CLASS="page_no" data-cite="703 f 3d 174" data-cite-type="PrimaryFederalReporter" data-cite-pageno="174" data-primary-citation="703 F.3d 149">[*174]</span> 1973) ("[A]

single instruction to a jury may not be judged in artificial isolation, but
must be viewed in the context of the overall charge.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority also focuses on the prosecution's summations, arguing that
the government did not use Caronia's promotion of Xyrem as evidence of
misbranding, but rather "prosecuted Caronia <i>for</i> his off-label promotion."
Maj. Op. at 158 (emphasis added). Suffice it to say, however, that any claim
that Caronia was convicted for his speech, as opposed to his conspiracy, is
belied by the fact that, as the majority rightly concedes, the district
court <span CLASS="page_no" data-cite="2012 bl 316528 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[**21]</span> explained the elements of conspiracy and misbranding to the jury and
instructed that each element must be shown beyond a reasonable doubt. We
presume that juries follow their instructions. <i>United States v. Williams</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1I3VHQ003?jcsearch=690%20f%203d%2070&amp;summary=yes#jcite">690 F.3d 70</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1I3VHQ003?jcsearch=690%20f%203d%2070&amp;summary=yes#jcite">77</a> (2d Cir.2012). Caronia, moreover, objected not at all to the
prosecution's references to his off-label promotion of Xyrem &mdash; and
unsurprisingly, since read in context, the government properly referred to
this promotion to prove Caronia's participation in a conspiracy to
distribute Xyrem for uses that its labeling neither described nor explained.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At bottom, the majority is troubled that "the simple promotion of a drug's
off-label use" can lead to criminal liability under the FDCA. Maj. Op. at
160. That is, where all that a drug manufacturer (or its representative)
does is sell a prescription drug and promote it for an off-label purpose,
the majority concludes that prosecution raises serious First Amendment
concerns &mdash; and regardless whether the off-label promotion is presented as
mere evidence or as the proscribed conduct itself. The majority's
conclusion, clearly stated, is that while speech might serve as evidence of
other types of mislabeling, such as false or deficient labeling, see Maj.
Op. at 161-62, a mislabeling charge simply may not rest on off-label
promotion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This is a departure from precedent. My conclusion here &mdash; that promotion of
a use may demonstrate an objective intent that the drug be used for that
purpose &mdash; has long been endorsed by this Circuit. <i>See United States v.</i>
<i>Writers &amp; Research, Inc.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3L0H0?jcsearch=113%20f%203d%208&amp;summary=yes#jcite">113 F.3d 8</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3L0H0?jcsearch=113%20f%203d%208&amp;summary=yes#jcite">11</a> (2d Cir.1997) ("We agree with the
district court that, as a matter of law, if 714X was promoted as a treatment
or cure for cancer, AIDS, or other diseases, it is subject to the
requirements of the FDCA. . . ."); <i>United States v. An Article Consisting of</i>
<i>216 Individually Cartoned Bottles</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3T8Q8?jcsearch=409%20f%202d%20734&amp;summary=yes#jcite">409 F.2d 734</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3T8Q8?jcsearch=409%20f%202d%20734&amp;summary=yes#jcite">739</a> (2d Cir.1969) ("It is
well settled that the intended use of a product may be determined from its
label, accompanying labeling, promotional material, advertising, and any
other relevant source. . . . Thus, Congress has made a judgment that a
product is subject to regulation as a drug if certain promotional claims are
made for it."). Such use of speech, moreover, has never been prohibited by
the First Amendment. <i>See Sorrell v. IMS Health Inc.</i>, <cite>___ U.S. ___</cite>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">2664-65</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a> (2011) ("[T]he <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> does
not prevent restrictions directed at commerce or conduct from imposing
incidental burdens on speech. That is why a ban on race-based hiring may
require employers to remove`White Applicants Only' signs; why an ordinance
against outdoor fires might forbid burning a flag; and why anti-trust laws
can prohibit agreements in restraint of trade.") (citations and some
internal quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is true that the introduction of Xyrem into interstate commerce by
Caronia's employer was generally legal so long as the drug was not intended
to be used for purposes that lacked adequate directions on its labeling. It
is also true that, absent Caronia's speech (and speech by other Orphan
<span CLASS="page_no" data-cite="703 f 3d 175" data-cite-type="PrimaryFederalReporter" data-cite-pageno="175" data-primary-citation="703 F.3d 149">[*175]</span> 
representatives), the jury likely would not have found that Xyrem was
intended for such off-label uses. Consistent with the <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a><span CLASS="page_no" data-cite="2012 bl 316528 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[**22]</span> ,
however, otherwise permissible conduct may become <i>impermissible</i> if
undertaken with a prohibited motive, and speech may be used as evidence of
such a motive. An employer, for example, is generally free to refuse to
promote an employee simply because he does not like the employee's attitude,
but he may not refuse to promote the employee because of her sex. <i>See</i>
<i>Wisconsin v. Mitchell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. at 487</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a> ("In <i>Hishon [v. King</i>
<i>&amp; Spalding</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAUL?jcsearch=467%20us%2069&amp;summary=yes#jcite">467 U.S. 69</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAUL?jcsearch=467%20us%2069&amp;summary=yes#jcite">78</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAUL?jcsearch=104%20supreme%20court%202229&amp;summary=yes#jcite">104 S.Ct. 2229</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAUL?jcsearch=81%20l%20ed%202d%2059&amp;summary=yes#jcite">81 L.Ed.2d 59</a> (1984)], we
rejected the argument that Title VII infringed employers' <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X10V1PA003?jcsearch=U.S.Const.%20Amend%20I&amp;summary=yes#jcite">First Amendment</a>
rights."). The First Amendment does not bar using the employer's speech to
demonstrate his discriminatory motive. <i>See Wisconsin v. Mitchell</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=508%20us%20476&amp;summary=yes#jcite">508 U.S. at 490</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CC9Q?jcsearch=113%20supreme%20court%202194&amp;summary=yes#jcite">113 S.Ct. 2194</a> (citing <i>Price Waterhouse v. Hopkins</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBP4?jcsearch=490%20us%20228&amp;summary=yes#jcite">490 U.S. 228</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBP4?jcsearch=490%20us%20228&amp;summary=yes#jcite">251-52</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBP4?jcsearch=109%20supreme%20court%201775&amp;summary=yes#jcite">109 S.Ct. 1775</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CBP4?jcsearch=104%20l%20ed%202d%20268&amp;summary=yes#jcite">104 L.Ed.2d 268</a> (1989) (plurality
opinion)). Indeed, as the crimes of attempt, conspiracy, and inducement
demonstrate, "[w]ords alone may constitute a criminal offense, even if they
spring from the anterior motive to effect political or social change."
<i>United States v. Freeman</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3UUMI?jcsearch=761%20f%202d%20549&amp;summary=yes#jcite">761 F.2d 549</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3UUMI?jcsearch=761%20f%202d%20549&amp;summary=yes#jcite">551</a> (9th Cir.1985) (Kennedy, J.).
<i>See generally</i> Kent Greenawalt, <i>Speech, Crime, and the Uses of Language</i> 6-7
(1989) (enumerating twenty-one crimes that "critically involve
communication," <i></i><cite>id. at 7</cite>). Simply put, that Caronia was otherwise free to
introduce Xyrem into interstate commerce does not give him a <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X10V1PA003?jcsearch=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a>
right to introduce it into interstate commerce for any intended purpose he
wished.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Caronia attempts to distinguish this line of authority by arguing that he
merely discussed "a perfectly lawful practice: the use of a lawful drug,
Xyrem, for off-label purposes." Appellant's Reply Br. at 10. But the fact
that a physician or a patient could legally use Xyrem for an off-label
purpose is not enough to make out Caronia's First Amendment claim. There
might be no law forbidding the consumption of arsenic. But this would not
endow Abby and Martha with a First Amendment right to offer arsenic-laced
wine to lonely old bachelors with the intent that they drink it. <i>See Arsenic</i>
<i>and Old Lace</i> (Warner Bros. Pictures 1944). And any statements Abby or Martha
made suggesting their intent &mdash; even if all of the statements were truthful
and not misleading &mdash; would not be barred from evidence by the First
Amendment simply because arsenic might legally be consumed.<a HREF="#fn501" name="fnref_fn501">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although Caronia relies heavily on the Supreme Court's decision in
<i>Thompson v. Western States Medical Center<span CLASS="page_no" data-cite="703 f 3d 176" data-cite-type="PrimaryFederalReporter" data-cite-pageno="176" data-primary-citation="703 F.3d 149">[*176]</span> </i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. 357</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=152%20l%20ed%202d%20563&amp;summary=yes#jcite">152 L.Ed.2d 563</a> (2002),

that case did not discuss the use of speech as evidence of intent. The
statute at issue in <i>Western States</i>, as the government conceded before the
Supreme Court, regulated speech directly rather than as evidence of intent.
<i>See id.</i> at 364-65, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a> ("[T]he pharmacy, licensed pharmacist, or
licensed physician compounding the drug may`not advertise or promote the
compounding of any particular drug, class of drug, or type of drug'. . . .")
(quoting <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a(c)&amp;summary=yes#jcite">21 U.S.C. &sect; 353a</a>(c)); <i>Western States</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 370-71</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a> ("The Government argues that advertising . . . is`a <i>fair</i>
<i>proxy</i> for actual or intended large-scale manufacturing. . . .'") (emphasis
added). The statute at issue in <i>Sorrell v. IMS Health Inc.</i>, <cite>___ U.S. ___</cite>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a> (2011), also targeted speech directly. <i>See</i>
<i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">id. at 2660</a> ("Pharmaceutical manufacturers and pharmaceutical marketers
shall not use prescriber-identifiable information <span CLASS="page_no" data-cite="2012 bl 316528 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[**23]</span> for marketing or promoting
a prescription drug unless the prescriber consents. . . .") (quoting Vt.
Stat. Ann., Tit. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X17BOQI003?jcsearch=Vt.%20Stat.%20Ann.,%20Tit.%2018,%20%204631(d)&amp;summary=yes#jcite">18, &sect; 4631</a>(d) (Supp.2010)). By contrast, Caronia's
conviction required a finding that Xyrem was intended by those responsible
for its labeling for an off-label use &mdash; a finding which "may be shown by the
circumstances that the article is, with the knowledge of such persons or
their representatives, offered and used for a purpose for which it is
neither labeled nor advertised." <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ49S003?jcsearch=21%20cfr%20201%20128&amp;summary=yes#jcite">21 C.F.R. &sect; 201.128</a>. <i>See generally</i> Krista
Hessler Carver, <i>A Global Vieiv of the First Amendment Constraints on FDA</i>, 63
Food &amp; Drug L.J. 151, 187-88 (2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Put another way, if the jury had concluded there was a reasonable doubt as
to whether Caronia and Orphan actually intended to sell Xyrem to Caronia's
customers &mdash; to introduce it into interstate commerce &mdash; then Caronia could
not have been convicted under <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">&sect; 331(a)</a>, no matter what he said. By contrast,
a pharmacy would violate the statute in <i>Western States</i> as soon as it
advertised the compounding of particular drugs. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 364-65</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a> (citing <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OM003?jcsearch=21%20U.S.C.%20%20353a(c)&amp;summary=yes#jcite">21 U.S.C. &sect; 353a</a>(c)). Similarly, a Vermont pharmacy
would violate the statute in <i>Sorrell</i> as soon as it disseminated
prescriber-identifying information for marketing purposes.
<i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2660</a>. Speech alone was sufficient to trigger liability under
the challenged statutes in those cases. Speech alone is not, however,
sufficient to sustain a conviction under <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  My analysis here is not original. The D.C. Circuit reached the same
conclusion in <i>Whitaker v. Thompson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20f%203d%20947&amp;summary=yes#jcite">353 F.3d 947</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20f%203d%20947&amp;summary=yes#jcite">953</a> (D.C.Cir.2004),<a HREF="#fn601" name="fnref_fn601">[fn6]</a>
in which a plaintiff argued that he had a <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X10V1PA003?jcsearch=u.s.%20const.%20amend.%20I&amp;summary=yes#jcite">First Amendment</a> right to label his
product with a drug claim despite its lack of FDA approval. The <i>Whitaker</i>
court disagreed, reasoning that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Assuming that the government may condition the sale of drugs on
    passage through the elaborate testing that the statute requires. . .
    . the key step is the []FDCA principle that classification of a
    substance as a`drug' turns on the nature of the claims advanced on
    its behalf. That principle, in turn, rests on the idea that claims
    about a product by its manufacturer and vendors, including product
    labeling, serve as evidence of the sellers' intent that consumers
    will purchase and use the product for a particular purpose &mdash; and,
    therefore, as evidence whether the product is or is not a drug. The
    question is whether this use of speech to infer intent, which in
    turn renders an otherwise permissible act unlawful, is
    constitutionally valid. In fact,
<span CLASS="page_no" data-cite="703 f 3d 177" data-cite-type="PrimaryFederalReporter" data-cite-pageno="177" data-primary-citation="703 F.3d 149">[*177]</span> 
    the First Amendment allows`the evidentiary use of speech to
    establish the elements of a crime or to prove motive or intent.'
    Thus it is constitutionally permissible for the FDA to use speech,
    in the form of labeling, to infer intent for purposes of determining
    that [the plaintiff's] proposed sale of saw palmetto extract would
    constitute the forbidden sale of an unapproved drug.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20F.3d%20947&amp;summary=yes#jcite">Id</a>.</i> (citations and paragraph breaks omitted). Caronia attempts to
distinguish <i>Whitaker</i> by arguing that "the drug itself in <i>Whitaker</i> could not
be sold lawfully, and so there were no lawful off-label uses to promote."
Appellant's Reply Br. at 15 (internal quotation marks and brackets omitted).
But the product in <i>Whitaker<span CLASS="page_no" data-cite="2012 bl 316528 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[**24]</span> </i> &mdash; "`saw palmetto,' an extract from the pulp and
seed of the dwarf American palm," <i>Whitaker</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6CQDU?jcsearch=353%20f%203d%20947&amp;summary=yes#jcite">353 F.3d at 948</a> &mdash; could be sold
lawfully so long as it was not a "drug," and whether it was a drug depended
entirely upon the plaintiffs speech, as evidence of his intent, when he
offered it for sale. That case is therefore indistinguishable from this
case; indeed, even if the FDA had not approved Xyrem for any medical uses at
all, Caronia could presumably have sold Xyrem as an industrial solvent if it
happened to be excellent at removing grease and grime.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Not every prohibition on conduct undertaken with a certain intent is
necessarily constitutional: the problem posed by a ban on "sending any
leaflet with the intent to influence another's vote" suggests the limits on
the analysis here. It remains the case, however, that the simple fact that
one is generally allowed to sell something does not imbue one with a
constitutional right to sell it for any intended purpose. And the
prohibition here on distributing drugs with the intent that they be used for
purposes not supported by their labeling is entirely consistent with the
broader purposes of the FDCA &mdash; namely, minimizing those occasions on which
patients use drugs that have not been shown to be safe and effective.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>III. Applying <i>Central Hudson</i></b>&nbsp;<b> and <i>Sorrell</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, even if using Caronia's speech as evidence of his intent was not
<i>necessarily</i> constitutionally permissible &mdash; in other words, even if the
protection afforded to commercial speech requires an analysis of this
question where the customers of a product like Xyrem may lawfully use it for
purposes not addressed in the label, and where the FDA does not purport to
regulate the claims made by unrelated third parties about the efficacy of
such uses, <i>see</i> George W. Evans &amp; Arnold I. Friede, <i>The Food and Drug</i>
<i>Administration's Regulation of Prescription Drug Manufacturer Speech: A</i>
<i>First Amendment Analysis</i>, 58 Food &amp; Drug L.J. 365, 390 (2003) &mdash; I believe
the correct application of commercial speech principles requires us to
uphold Caronia's conviction. I agree with the majority that our analysis is
guided by <i>Central Hudson Gas &amp; Electric Corp. v. Public Service Commission</i>
<i>of New York</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. 557</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=65%20l%20ed%202d%20341&amp;summary=yes#jcite">65 L.Ed.2d 341</a> (1980), and
<i>Sorrell v. IMS Health Inc.</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a>
(2011). I conclude, however, that the FDCA's misbranding provision survives
the scrutiny required by those cases because it directly advances a
substantial government interest and is narrowly drawn to further that
interest.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "[o]ne of the [FDCA]'s core objectives is to ensure that any product
regulated by the FDA is safe and effective for its intended use." <i>Brown &amp;</i>
<i>Williamson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. at 133</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a> (2000) (internal quotation marks
omitted). The FDCA is meant to achieve this objective through a rigorous
premarket approval process. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>. Under this process, a
<span CLASS="page_no" data-cite="703 f 3d 178" data-cite-type="PrimaryFederalReporter" data-cite-pageno="178" data-primary-citation="703 F.3d 149">[*178]</span> 
manufacturer may not sell a drug without first providing proof to the FDA
that the drug is "safe for use" and "effective in use." <i>See </i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)&amp;summary=yes#jcite">id. &sect; 355(b)</a>.
There must be "substantial evidence," including evidence from clinical
investigations, "that the drug will have the effect it purports or is
represented to have." <i></i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">Id. &sect; 355(d)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This process is a central, if not <i>the<span CLASS="page_no" data-cite="2012 bl 316528 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[**25]</span> </i> central, feature of the FDCA. Prior
to the passage of the FDCA, the government could combat misleading drug
claims only through post-market enforcement actions. The 1938 Act's "most
substantial innovation" was to require approval of a drug's safety before it
could enter the market. <i>Wyeth</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. at 566</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>. This
innovation became even more important after Congress amended the FDCA in
1962 to also require premarket approval of a drug's effectiveness for its
stated uses. <i>See</i> Drug Amendments of 1962, Pub.L. No. <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=USACTS%2087-781&amp;summary=yes#jcite">87-781</a>, <cite>&sect; 102</cite>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=76%20stat%20780&amp;summary=yes#jcite">76 Stat. 780</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=76%20stat%20780&amp;summary=yes#jcite">781</a>. Behind the 1962 amendments were concerns that doctors
could not adequately evaluate frequently misleading claims by drug
manufacturers without a body of objective, reliable information. <i>See, e.g.</i>,
Henry A. Waxman, <i>A History of Adverse Drug Experiences: Congress Had Ample</i>
<i>Evidence to Support Restrictions on the Promotion of Prescription Drugs</i>, 58
Food &amp; Drug L.J. 299, 301-08 (2003); Alan H. Kaplan, <i>Fifty Years of Drug</i>
<i>Amendments Revisited</i>, 50 Food &amp; Drug L.J. 179, 184-85 (1995).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has accordingly stated that "[p]reserving the
effectiveness and integrity of the FDCA's new drug approval process is
clearly an important governmental interest." <i>Western States</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 369</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>. Given the benefits of premarket approval,
"the Government has every reason to want as many drugs as possible to be
subject to that approval process." <i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20U.S.%20357&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDCA's prohibition on off-label marketing directly advances this
interest. If drug manufacturers were allowed to promote FDA-approved drugs
for nonapproved uses, they would have little incentive to seek FDA approval
for those uses. Prohibiting such promotion is thus "one of the few
mechanisms available" to encourage participation in the approval process.
<i>Washington Legal Foundation v. Friedman</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3UMUU?jcsearch=13%20f%20supp%202d%2051&amp;summary=yes#jcite">13 F.Supp.2d 51</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3UMUU?jcsearch=13%20f%20supp%202d%2051&amp;summary=yes#jcite">72</a> (D.D.C.1998),
<i>vacated in part, Washington Legal Foundation v. Henney</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3IN8E?jcsearch=202%20f%203d%20331&amp;summary=yes#jcite">202 F.3d 331</a>
(D.C.Cir.2000). And premarket approval improves drug safety and
effectiveness only to the extent that drugs are not sold without such
approval.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In concluding that prohibiting off-label promotion does not directly
advance the government's interests, the majority places great weight on the
fact that "physicians can prescribe, and patients can use, drugs for
off-label purposes." Maj. Op. at 166. But this is also true for substances
that have not been approved by the FDA for any medical use at all. The law
generally permits a hardware store to sell turpentine, and though such
conduct may not be advisable, the law generally permits a consumer to
purchase that turpentine and use it as a pain reliever. Under the majority's
reasoning, then, any substance that may be legally sold for <i>some</i> purpose may
be promoted by its manufacturer for <i>any</i> purpose &mdash; so long as the
manufacturer's statements are merely unsubstantiated, rather than
demonstrably false or misleading. But this reasoning would invalidate the
very definitions of "drug" and "device" that undergird the entire FDCA.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority also emphasizes that the prohibition on off-label promotion
applies only to a "particular class of speakers" &mdash; namely, drug
manufacturers. Maj. Op. at 166. But drug manufacturers are the precise group
that <span CLASS="page_no" data-cite="2012 bl 316528 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[**26]</span> the government must encourage
<span CLASS="page_no" data-cite="703 f 3d 179" data-cite-type="PrimaryFederalReporter" data-cite-pageno="179" data-primary-citation="703 F.3d 149">[*179]</span> 
to participate in the new drug approval process. Indeed, if the prohibition
applied to any broader class of speakers, it would likely fail <i>Central</i>
<i>Hudson's</i> fourth requirement that a regulation be "narrowly drawn." The
Supreme Court's decision in <i>Sorrell</i> is thus inapposite in the present
circumstances. The statute there did not directly advance Vermont's interest
in protecting patient privacy because it applied to only a small subset of
those groups that could possibly compromise patient privacy.
<i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2668</a>. Drug manufacturers, in contrast, form the entirety of
those speakers that could possibly undermine the new drug approval process
by not participating in it.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, allowing drug manufacturers to promote off-label uses would
undermine the FDA's approval process for not only new uses of pre-approved
drugs, but also for entirely new drugs. As explained above, when determining
whether a drug should be approved, the FDCA requires consideration not only
of the drug's safety, but also its effectiveness. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20usc%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>; <i>United</i>
<i>States v. Rutherford</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C9PQ?jcsearch=442%20us%20544&amp;summary=yes#jcite">442 U.S. 544</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C9PQ?jcsearch=442%20us%20544&amp;summary=yes#jcite">555</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=99%20supreme%20court%202470&amp;summary=yes#jcite">99 S.Ct. 2470</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C9PQ?jcsearch=61%20l%20ed%202d%2068&amp;summary=yes#jcite">61 L.Ed.2d 68</a> (1979)
("[T]he [FDA] Commissioner generally considers a drug safe when the expected
therapeutic gain justifies the risk entailed by its use."). If a drug
manufacturer must be allowed to distribute a drug for any use so long as it
is approved for one use, the government's balancing of a drug's benefits
against its risks becomes very difficult or even impossible. Drugs viewed as
safe for certain uses might be considered unsafe overall if the benefits and
risks being weighed are not for a specific intended use but rather for any
use at all, whether supported by evidence or not.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The prohibition of off-label promotion is thus not simply a
"paternalistic" attempt to shield physicians and patients from truthful
information. See Maj. Op. at 166. Rather, it is a necessary tool for the
effective functioning of a regulatory system that the Supreme Court has
endorsed as legitimate. The majority implies that prohibiting off-label
promotion is unconstitutionally "paternalistic" regardless whether the drug
manufacturer's claims are addressed to a physician or to a patient. <i>See,</i>
<i>e.g.</i>, Maj. Op. at 166 ("[P]rohibiting off-label promotion by a
pharmaceutical manufacturer while simultaneously allowing off-label
use`paternalistically' interferes with the ability of physicians <i>and</i>
<i>patients</i> to receive potentially relevant treatment information. . . .")
(emphasis added). But if drug manufacturers have a First Amendment right to
distribute drugs for any use to physicians or even directly to patients,
then the entire FDCA may well be unconstitutional.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prohibiting off-label promotion by drug manufacturers is also the least
restrictive way of advancing the government's interests. Although the
majority asserts various alternatives, none would be similarly effective. A
disclaimer system or required listing of intended uses would provide
manufacturers much less incentive to submit their drugs for FDA approval,
and in turn encourage promotion based on data much less reliable <span CLASS="page_no" data-cite="2012 bl 316528 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[**27]</span> than the
clinical investigations required under <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(d)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(d).<a HREF="#fn701" name="fnref_fn701">[fn7]</a> A ceiling on
off-label prescriptions
<span CLASS="page_no" data-cite="703 f 3d 180" data-cite-type="PrimaryFederalReporter" data-cite-pageno="180" data-primary-citation="703 F.3d 149">[*180]</span> 
would require collecting data from countless numbers of doctors and patients
and, given the medical uncertainties involved, could needlessly (and
simultaneously) result in the denial of some effective treatments and the
over-prescription of ineffective and even dangerous ones. Finally, a ban on
off-label prescriptions would be no better. Indeed, it would constitute an
unprecedented intrusion into the practice of medicine, and would result in
perhaps an even greater restriction on speech. <i>See Central Hudson</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 563-64</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a> (government free to ban "commercial
speech related to illegal activity"). And again, because a product's very
definition as a "drug" depends upon its intended use (which is often
established by the manufacturer's speech), it is unclear why the majority's
less-restrictive-alternatives analysis is not equally applicable to the
FDCA's entire scheme of drug regulation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  That the FDCA is both "content- and speaker-based" within the meaning of
<i>Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2663</a>, does not alter the foregoing analysis. <i>Every</i>
commercial speech case, by its very nature, involves both content- and
speaker-based speech restrictions. <i>See Va. State Bd. of Pharmacy v. Va.</i>
<i>Citizens Consumer Council, Inc.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">425 U.S. 748</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">761</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=96%20supreme%20court%201817&amp;summary=yes#jcite">96 S.Ct. 1817</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C951?jcsearch=48%20l%20ed%202d%20346&amp;summary=yes#jcite">48 L.Ed.2d 346</a> (1976) ("If there is a kind of commercial speech . . . it
must be distinguished by its content."). Yet the Supreme Court has long
acknowledged &mdash; and acknowledged again in <i>Sorrell</i> &mdash; that "the government's
legitimate interest in protecting consumers from commercial harms explains
why commercial speech can be subject to greater governmental regulation than
noncommercial speech." <i>Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2672</a> (internal quotation marks
omitted). Indeed, the Supreme Court struck down the ban on energy
advertising in <i>Central Hudson</i> because a <i>content-based</i> less-restrictive
alternative existed. <i>See Cent. Hudson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 571</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>
("[T]he Commission could attempt to restrict the format and content of
Central Hudson's advertising. It might, for example, require that the
advertisements include information about the relative efficiency and expense
of the offered service, both under the current conditions and for the
foreseeable future."). <i>Sorrell</i> did not purport to overrule the <i>Central</i>
<i>Hudson</i> test, which has guided First Amendment doctrine in this area for
thirty years.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, in <i>Sorrell</i> the Court noted that Vermont did not argue that its
challenged statute "will prevent false or misleading speech."
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2672</a>. Rather, Vermont's "interest in burdening the speech of
detailers instead turn [ed] on nothing more than a difference of opinion."
<i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">Id</a>.</i> In contrast, Congress intended the FDA approval process to prevent
dangerous products with false or misleading labels from entering the market,
and also to provide a base of reliable, objective information about
prescription drugs that could help physicians and patients identify
potentially misleading claims. Clearly this is the type of statute to which
<i>Sorrell</i> intended that <i>Central Hudson</i> would still apply.<span CLASS="page_no" data-cite="703 f 3d 181" data-cite-type="PrimaryFederalReporter" data-cite-pageno="181" data-primary-citation="703 F.3d 149">[*181]</span> <a HREF="#fn801" name="fnref_fn801">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">

</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is certainly true that "the`fear that people would make bad decisions
if given <span CLASS="page_no" data-cite="2012 bl 316528 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[**28]</span> truthful information' cannot justify content-based burdens on
speech." <i>Sorrell</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2670-71</a> (quoting <i>Thompson</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 374</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>). But this does not mean that conveying non-demonstrably
false information to consumers must take precedence over all competing
government interests. Our system of drug regulation developed to protect
consumers from misleading and unsubstantiated claims about drugs' safety and
efficacy, and the prohibition on off-label promotion by drug manufacturers
is essential to maintaining the effectiveness of that system. Therefore,
even if such a prohibition is considered a direct regulation of speech, it
is a regulation that directly advances a substantial government interest in
a manner not more extensive than necessary to serve that interest. I would
thus find it constitutional under <i>Central Hudson</i> and <i>Sorrell.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>IV. The Verdict Sheet and the Jury's Verdict</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because I believe that the FDCA's misbranding provision may
constitutionally be applied to Caronia's conduct, I next address Caronia's
remaining arguments: (1) that the district court erred in breaking down the
conspiracy charge on the verdict sheet into two subissues; and (2) that the
jury rendered an inconsistent verdict by convicting Caronia of conspiring to
introduce or deliver for introduction into interstate commerce a misbranded
drug while finding him not guilty of conspiring to do an act to a drug that
would result in it being misbranded.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The first count of a two-count information charged Caronia with conspiring
both (1) to introduce into interstate commerce a drug that was misbranded
and (2) to do an act with respect to a drug that would result in that drug
being misbranded.<a HREF="#fn901" name="fnref_fn901">[fn9]</a> With respect to that count, the district court
submitted a two-part verdict sheet to the jury which asked:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. How do you find the defendant, ALFRED CARONIA, on Count One of
    the Information?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) Conspiracy to introduce or deliver for introduction into
    interstate commerce a drug, Xyrem, that was mis-branded?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      NOT GUILTY ___ GUILTY___
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) Conspiracy to do an act with respect to a drug, Xyrem, when
    such drug was held for sale after shipment in interstate commerce
    when such act would result in Xyrem being misbranded?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      NOT GUILTY ___ GUILTY ___
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
The jury concluded that Caronia was guilty with respect to question (a) and
not guilty with respect to question (b).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Caronia argues that the district court erred by subdividing the conspiracy
charge on the verdict sheet because, he claims, the district court
essentially split the charge into two separate counts. But we have held that
a conspiracy charge may allege an agreement to commit more than one offense,
<i>see United States v. Coriaty</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6BHIP?jcsearch=300%20f%203d%20244&amp;summary=yes#jcite">300 F.3d 244</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X6BHIP?jcsearch=300%20f%203d%20244&amp;summary=yes#jcite">250</a> (2d Cir.2002) ("We have
upheld convictions for multi-object conspiracies charged in the conjunctive
even when there was insufficient evidence to support one of the objects of
the conspiracy."), and that a district court does not impermissibly
constructively amend a charge by

subdividing <span CLASS="page_no" data-cite="703 f 3d 182" data-cite-type="PrimaryFederalReporter" data-cite-pageno="182" data-primary-citation="703 F.3d 149">[*182]</span> an offense into parts, <i>see United States v. McCourty</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ATGLQ003?jcsearch=562%20f%203d%20458&amp;summary=yes#jcite">562 F.3d 458</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ATGLQ003?jcsearch=562%20f%203d%20458&amp;summary=yes#jcite">470</a> (2d Cir.2009) ("No constructive amendment resulted when
the District Court broke the <span CLASS="page_no" data-cite="2012 bl 316528 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[**29]</span> single offense into two parts to be addressed
by the jury."). I therefore find no error in the verdict sheet.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Caronia further argues that the jury rendered an inconsistent verdict by
finding him not guilty of conspiring to do an act to a drug that would
result in it being misbranded while finding him guilty of conspiring to
introduce or deliver for introduction into interstate commerce a mis-branded
drug. But these verdicts were not inconsistent &mdash; for example, the jury may
have concluded that the drug was not being held for sale after shipment in
interstate commerce. And even assuming the verdicts were inconsistent, "the
convicted defendant's protection against an irrational verdict is his
ability to have the courts review the sufficiency of the evidence to support
his conviction," <i>United States v. Acosta</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X38435?jcsearch=17%20f%203d%20538&amp;summary=yes#jcite">17 F.3d 538</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X38435?jcsearch=17%20f%203d%20538&amp;summary=yes#jcite">545</a> (2d Cir.1994).
There was ample evidence for a reasonable jury to conclude beyond a
reasonable doubt that Caronia conspired to introduce or deliver for
introduction into interstate commerce a misbranded drug. Indeed, Caronia was
caught on tape with Dr. Gleeson suggesting off-label uses of Xyrem to
doctors. I therefore see no error in the verdict sheet and no inconsistency
requiring reversal or vacatur in the jury's verdict.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      * * *
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The majority has chosen to apply heightened scrutiny to this case, though
we have not done so in other cases involving the use of speech as evidence
of intent &mdash; for example, in antidiscrimination actions or prosecutions for
criminal inducement, attempt, and conspiracy &mdash; cases I cannot meaningfully
distinguish from this one. The majority's decision today extends heightened
scrutiny further than the Supreme Court ever has, and calls into question a
fundamental regime of federal regulation that has existed for more than a
century. I respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> The FDA has exempted certain drugs from the requirement that their
labels contain adequate directions for lay use. <i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OI003?jcsearch=21%20U.S.C.%20%20352(f)&amp;summary=yes#jcite">21 U.S.C. &sect; 352</a>(f); <i>see,</i>
<i>e.g.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ498003?jcsearch=21%20cfr%20201%20100&amp;summary=yes#jcite">21 C.F.R. &sect; 201.100</a> (exempting certain prescription drugs); <i>cf. United</i>
<i>States v. An Article of Device</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3J4EE?jcsearch=731%20f%202d%201253&amp;summary=yes#jcite">731 F.2d 1253</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X3J4EE?jcsearch=731%20f%202d%201253&amp;summary=yes#jcite">1259</a> (7th Cir.1984)
("Obviously there are many medical devices which would be ineffective at
best, and dangerous at worst, if left in the hands of a layman, and [FDA
regulations] appear[] to deem any such devices`misbranded' and thus subject
to seizure. However, the regulations provide several exemptions from
the`adequate directions for use' requirement."). Caronia does not argue that
any such exemption applies here.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> <i>See</i> Wikipedia, Hamlin's Wizard Oil,
hltp://en.wikipedia.org/wiki/Hamlin's_Wizard_Oil (last visited May 30,
2012); <i>cf. United Stales v. Rutherford</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C9PQ?jcsearch=442%20us%20544&amp;summary=yes#jcite">442 U.S. 544</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C9PQ?jcsearch=442%20us%20544&amp;summary=yes#jcite">558</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=99%20supreme%20court%202470&amp;summary=yes#jcite">99 S.Ct. 2470</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5C9PQ?jcsearch=61%20l%20ed%202d%2068&amp;summary=yes#jcite">61 L.Ed.2d 68</a> (1979) ("Since the turn of the century, resourceful
entrepreneurs have advertised a wide variety of purportedly simple and
painless cures for cancer, including liniments of turpentine, mustard, oil,
eggs, and ammonia; peat moss; arrangements of colored floodlamps; pastes
made from glycerin and limburger cheese; mineral tablets; and`Fountain of
Youth' mixtures of spices, oil, and suet. . . . [H]istorical experience does
suggest why Congress could reasonably have determined to protect . . .
patients[] from the vast range of self-styled panaceas that inventive minds
can devise.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn301" name="fn301">[fn3]</a></span> This was not the only evidence on which the government relied. As the
majority acknowledges, Xyrem is a "powerful central nervous system
depressant" that the FDA requires to bear a "black box" warning (the most
serious warning placed on prescription medicine) in light of its potential
side effects, which include seizure, respiratory depression, coma, and
death. Maj. Op. at 155. Yet in the taperecorded meeting of October 26, 2005
between Caronia and Dr. Charno, to which the majority refers, Caronia
described Xyrem as "a very safe drug," with no contraindications. At
Caronia's second meeting with Dr. Charno on November 2, Dr. Gleason, one of
Caronia's co-conspirators, described many potential uses for Xyrem,
including in the treatment of obesity and chronic fatigue, and added that
"for the problems with insomnia there's no better drug, no safer drug, it's
as safe as Ambien and Sonata. . . ." Caronia later admitted that his
employer required him to meet an annual sales quota of 520 bottles of Xyrem
in 2005, the year these conversations took place, and that he was unable to
meet it. In fact, the salaries of Orphan's sales personnel depended to a
significant degree on meeting sales targets, and in 2005 Caronia was ranked
near the very bottom of Orphan's national sales force.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn401" name="fn401">[fn4]</a></span> Notably, Caronia himself does not argue that the district court's
instruction was improper. While I disagree with the majority's conclusion
that the jury was improperly instructed, moreover, I note to be clear that
an identical instruction <i>could</i> be problematic in a different case of alleged
misbranding &mdash; where a defendant argued, for example, that the drug's
labeling included adequate directions for uses that were not FDA-approved.
<i>Cf. United States v. Articles of Drug</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X49PBR?jcsearch=585%20f%202d%20575&amp;summary=yes#jcite">585 F.2d 575</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X49PBR?jcsearch=585%20f%202d%20575&amp;summary=yes#jcite">585</a> n. 20 (3d Cir.1978)
(instructing the district court, which had "entered no findings of fact as
to misbranding" and did not consider the "argument that the drugs were
labeled sufficiently for lay use," to "consider these factors" on remand).
Provided a drug bears adequate labeling for an unapproved use, a defendant
distributing such a drug cannot be convicted under <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a) for
introducing a misbranded drug into interstate commerce. Labeling a drug with
directions for unapproved uses, however, may violate <i>another</i> provision of
the FDCA. <i>See, e.g., Wyeth v. Levine</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">555 U.S. 555</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ALNB4003?jcsearch=555%20us%20555&amp;summary=yes#jcite">568</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ALNB4003?jcsearch=129%20supreme%20court%201187&amp;summary=yes#jcite">129 S.Ct. 1187</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1ALNB4003?jcsearch=173%20l%20ed%202d%2051&amp;summary=yes#jcite">173 L.Ed.2d 51</a> (2009) ("The FDA's premarket approval of a new drug
application includes the approval of the exact text in the proposed label.
<i>See</i><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>; <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XMJ54C003?jcsearch=21%20C.F.R.%20%20314.105(b)&amp;summary=yes#jcite">21 C.F.R. &sect; 314.105</a>(b) (2008). Generally speaking, a
manufacturer may only change a drug label after the FDA approves a
supplemental application.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn501" name="fn501">[fn5]</a></span> Indeed, speech encouraging others to engage in certain legal conduct
has long been <i>directly</i> regulated or prohibited in a variety of areas. For
example, an insider who is privy to an impending corporate merger is
prohibited from telling a friend that one of those companies is a good buy &mdash;
even if that statement is truthful and even if the friend (who does not
realize that she has just been made privy to material nonpublic information)
may legally buy stock in that company. <i>See United States v. Gansman</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1G92HI003?jcsearch=657%20f%203d%2085&amp;summary=yes#jcite">657 F.3d 85</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1G92HI003?jcsearch=657%20f%203d%2085&amp;summary=yes#jcite">92</a> (2d Cir.2011) (elements of tipper liability); <i>United States</i>
<i>v. Falcone</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X510JN?jcsearch=257%20f%203d%20226&amp;summary=yes#jcite">257 F.3d 226</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X510JN?jcsearch=257%20f%203d%20226&amp;summary=yes#jcite">234</a> (2d Cir.2001) (elements of tippee liability).
Each of two corporations may be free to raise its prices, but the Sherman
Act forbids them from discussing such a course of action. <i>See In re High</i>
<i>Fructose Corn Syrup Antitrust Litig.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X17NFVQNB5G0?jcsearch=295%20f%203d%20651&amp;summary=yes#jcite">295 F.3d 651</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X17NFVQNB5G0?jcsearch=295%20f%203d%20651&amp;summary=yes#jcite">654</a> (7th Cir.2002)
(Posner, J.); Louis Kaplow, <i>On the Meaning of Horizontal Agreements in</i>
<i>Competition Law</i>, 99 Calif. L.Rev. 683 (2011). Likewise, nonlawyers are
forbidden from giving legal advice even if the advice is sound, <i>see, e.g.,</i>
<i>People v. Alfani</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X618KS?jcsearch=227%20new%20york%20334&amp;summary=yes#jcite">227 N.Y. 334</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X618KS?jcsearch=125%20north%20eastern%20671&amp;summary=yes#jcite">125 N.E. 671</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X618KS?jcsearch=125%20north%20eastern%20671&amp;summary=yes#jcite">673</a> (1919), and unlicensed
laypersons may not provide medical diagnoses, regardless of their accuracy,
<i>see, e.g., Locke v. Ionia Circuit Judge</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XATM7FQNB5G0?jcsearch=184%20michigan%20535&amp;summary=yes#jcite">184 Mich. 535</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XATM7FQNB5G0?jcsearch=151%20north%20western%20623&amp;summary=yes#jcite">151 N.W. 623</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XATM7FQNB5G0?jcsearch=151%20north%20western%20623&amp;summary=yes#jcite">625</a>
(1915); <i>Commonwealth v. Jewelle</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4F8KQ?jcsearch=199%20massachusetts%20558&amp;summary=yes#jcite">199 Mass. 558</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4F8KQ?jcsearch=85%20north%20eastern%20858&amp;summary=yes#jcite">85 N.E. 858</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X4F8KQ?jcsearch=85%20north%20eastern%20858&amp;summary=yes#jcite">859</a> (1908).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn601" name="fn601">[fn6]</a></span> Then-Judge Roberts was a member of the unanimous panel.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn701" name="fn701">[fn7]</a></span> Indeed, experts have concluded that most prescriptions for off-label
use have little or no scientific support. <i>See</i> Randall S. Stafford,
<i>Regulating Off-Label Drug Use: Rethinking the Role of the FDA</i>, 358 New Eng.
J. Med. 1427, 1427 (2008) ("In an examination of off label prescribing of
160 common drugs, off-label use was . . . found to account for 21 % of all
prescriptions, and most off-label drug uses (73%) were shown to have little
or no scientific support.") (citing David C. Radley, Stan N. Finkelstein &amp;
Randall S. Stafford, <i>Off-Label Prescribing Among Office-Based Physicians</i>,
166 Archives of Internal Med. 1021 (2006)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn801" name="fn801">[fn8]</a></span> Nor does the fact that <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/XEI5MC003?jcsearch=21%20U.S.C.%20%20331(a)&amp;summary=yes#jcite">21 U.S.C. &sect; 331</a>(a) applies criminal penalties
necessarily mean that it warrants heightened scrutiny. The case that the
majority cites for this proposition, <i>Holder v. Humanitarian Law Project</i>, did
not premise its application of heightened scrutiny on the statute's criminal
penalties. <i>See</i><cite>___ U.S. ___</cite>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=130%20supreme%20court%202705&amp;summary=yes#jcite">130 S.Ct. 2705</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=130%20supreme%20court%202705&amp;summary=yes#jcite">2724</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1DF66M003?jcsearch=177%20l%20ed%202d%20355&amp;summary=yes#jcite">177 L.Ed.2d 355</a> (2010).
Moreover, the Supreme Court has previously applied <i>Central Hudson</i> to
statutes that provide for or trigger criminal punishment for speech. <i>See</i>
<i>Greater New Orleans Broad. Ass'n, Inc. v. United States</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2T66K?jcsearch=527%20us%20173&amp;summary=yes#jcite">527 U.S. 173</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2T66K?jcsearch=527%20us%20173&amp;summary=yes#jcite">177</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=119%20supreme%20court%201923&amp;summary=yes#jcite">119 S.Ct. 1923</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X2T66K?jcsearch=144%20l%20ed%202d%20161&amp;summary=yes#jcite">144 L.Ed.2d 161</a> (1999); <i>44 Liquormart, Inc. v. Rhode Island</i>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">517 U.S. 484</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=517%20us%20484&amp;summary=yes#jcite">490</a> n. 3, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=116%20supreme%20court%201495&amp;summary=yes#jcite">116 S.Ct. 1495</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CCQF?jcsearch=134%20l%20ed%202d%20711&amp;summary=yes#jcite">134 L.Ed.2d 711</a> (1996); <i>Bolger v.</i>
<i>Youngs Drug Products Corp.</i>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAN7?jcsearch=463%20us%2060&amp;summary=yes#jcite">463 U.S. 60</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAN7?jcsearch=463%20us%2060&amp;summary=yes#jcite">61-62</a>, <a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/1?citation=103%20supreme%20court%202875&amp;summary=yes#jcite">103 S.Ct. 2875</a>,
<a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X5CAN7?jcsearch=77%20l%20ed%202d%20469&amp;summary=yes#jcite">77 L.Ed.2d 469</a> (1983).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn901" name="fn901">[fn9]</a></span> The second count charged Caronia with doing an act with respect to a
drug that resulted in that drug being misbranded.
</p></div>
<!--BBLS DD 1750581510147-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1IUBCK003/history">Direct History (3)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1IUBCK003/analysis">Case Analysis (14)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1IUBCK003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
14
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Conviction Vacated, Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/3755babe47b344ed8418839cff2740e9/document/X1Q6L94U4782">09-05006 (2d Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Criminal Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/3755babe47b344ed8418839cff2740e9/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "3755babe47b344ed8418839cff2740e9";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY26e752&previousPageId=&previousActivityInstanceId=ENTITY3c6140&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:35:17-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1IUBCK003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY3c6140&previousPageId=&previousActivityInstanceId=ENTITY77df2e&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:35:14-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1IUBCK003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1IUBCK003";
$('#page_loader').show().spin();
JUDGE_IDS=["16564343","1842856","1857275"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
